Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.37 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ACE | P12821 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | CASP7 | P55210 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfotep SCHEMBL20838874 | 0.83 | MME (0.34) | MMEKMT2AMEN1 | |
| SCHEMBL12156551 | 0.83 | MAPT (0.37) | MMEKMT2AMEN1MAPTKDM4E | |
| SCHEMBL15876942 | 0.82 | MME (0.33) | MME | |
| SCHEMBL859388 | 0.77 | MME (0.46) | MME | |
| SCHEMBL10022759 | 0.76 | MME (0.33) | MME | |
| SCHEMBL13544349 | 0.76 | KMT2A (0.45) | MMEKMT2AMEN1CSNK2A2CSNK2B | |
| SCHEMBL7199030 | 0.76 | MME (0.45) | MMEMAPTACE | |
| SCHEMBL19604387 | 0.75 | KMT2A (0.44) | MMEKMT2AMEN1CSNK2A2CSNK2B | |
| SCHEMBL8818955 | 0.73 | MME (0.42) | MMEKDM4EPOLB | |
| SCHEMBL3646561 | 0.72 | MME (0.43) | MMEKMT2AMEN1CSNK2A2CSNK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 494 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4580694-A1 | SEALANTS FOR TISSUE CLOSURE | Ethicon, Inc. (US) | 2025-07-09 | — | — | EP | claimed |
| WO-2024047443-A1 | SEALANTS FOR TISSUE CLOSURE | ETHICON, INC. (US) | 2024-03-07 | — | — | WO | claimed |
| US-20240066178-A1 | SEALANTS FOR TISSUE CLOSURE | ETHICON, INC. (US) | 2024-02-29 | — | — | US | claimed |
| US-20230310320-A1 | SOLUBLE MICROCARRIER, METHOD FOR MANUFACTURING AND METHOD OF USE THEREOF | NATIONAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY (TW) | 2023-10-05 | — | — | US | claimed |
| US-10953073-B2 | XTEN conjugate compositions and methods of making same | AMUNIX PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | claimed |
| WO-2012162490-A1 | NANOZYME COMPOSITIONS AND METHODS OF SYNTHESIS AND USE THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2012-11-29 | — | — | WO | claimed |
| JP-4193917-B2 | — | — | 2008-12-10 | — | — | JP | claimed |
| EP-0832201-B1 | A SAMPLE PRESENTATION APPARATUS FOR MASS SPECTROMETRY | UNIV ARIZONA (US) | 2005-10-05 | — | — | EP | claimed |
| EP-1392255-A1 | NANOPARTICLES MADE OF PROTEIN WITH COUPLED APOLIPOPROTEIN E FOR PENETRATION OF THE BLOOD-BRAIN BARRIER AND METHODS FOR THE PRODUCTION THEREOF | LTS Lohmann Therapie-Systeme AG (DE) | 2004-03-03 | — | — | EP | claimed |
| US-20030149173-A1 | Crosslinked polymer compositions and methods for their use | RHEE WOONZA M (US) | 2003-08-07 | — | — | US | claimed |
| US-20030143638-A1 | Antibody/carrier complex, process for producing the same, method of controlling antigen-antibody reaction by using the same and immunoassay method | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 2003-07-31 | — | — | US | claimed |
| WO-2002089776-A1 | NANOPARTICLES MADE OF PROTEIN WITH COUPLED APOLIPOPROTEIN E FOR PENETRATION OF THE BLOOD-BRAIN BARRIER AND METHODS FOR THE PRODUCTION THEREOF | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2002-11-14 | — | — | WO | claimed |
| US-20020013408-A1 | Cross-linked polymer compositions and methods for their use | ANGIODEVICE INTERNATIONAL GMBH (CH) | 2002-01-31 | — | — | US | claimed |
| US-20010003126-A1 | Method of making crosslinked polymer matrices in tissue treatment applications | ANGIODEVICE INTERNATIONAL GMBH (CH) | 2001-06-07 | — | — | US | claimed |
| US-6093541-A | WITH METAL PRESENTATION SURFACE HAVING IMMOBILIZED COMPLEX OF TETHERING MOLECULE AND DIGESTION MOLECULE; FOR RAPID AND EFFICIENT ANALYSIS OF BIOMOLECULES USING MATRIX-ASSISTED LASER DESORPTION/IONIZATION TECHNIQUE | ARIZONA STATE UNIVERSITY BOARD OF REGENTS (US) | 2000-07-25 | — | — | US | claimed |
| JP-2000502380-A | — | — | 2000-02-29 | — | — | JP | claimed |
| EP-0876165-A1 | CROSSLINKED POLYMER COMPOSITIONS AND METHODS FOR THEIR USE | COLLAGEN CORPORATION (US) | 1998-11-11 | — | — | EP | claimed |
| WO-1997022371-A9 | CROSSLINKED POLYMER COMPOSITIONS AND METHODS FOR THEIR USE | — | 1997-09-04 | — | — | WO | claimed |
| WO-1997022371-A1 | CROSSLINKED POLYMER COMPOSITIONS AND METHODS FOR THEIR USE | COLLAGEN CORPORATION (US) | 1997-06-26 | — | — | WO | claimed |
| US-12599624-B2 | Biodegradable lung sealants | ETHICON, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| EP-4580690-B1 | BIODEGRADABLE LUNG SEALANTS | ETHICON INC (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4676553-A1 | MEDICAL SEALANTS | Ethicon, Inc. (US) | 2026-01-14 | — | — | EP | disclosed |
| US-20250352663-A1 | Nanoclusters Functionalized with Adenosine Triphosphate or an Analogue and Their Use | UNIV LELAND STANFORD JUNIOR (US) | 2025-11-20 | — | — | US | disclosed |
| EP-4598596-A1 | FLOWABLE HYDROGEL HYDROCOLLOID COMPOSITE SEALANT | Ethicon, Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| EP-4580690-A1 | BIODEGRADABLE LUNG SEALANTS | Ethicon, Inc. (US) | 2025-07-09 | — | — | EP | disclosed |
| EP-4580694-A1 | SEALANTS FOR TISSUE CLOSURE | Ethicon, Inc. (US) | 2025-07-09 | — | — | EP | disclosed |
| US-20250177558-A1 | Functionalized Nanoclusters and Their Use in Treating Bacterial Infections | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2025-06-05 | — | — | US | disclosed |
| US-12280021-B2 | Affinity medicant conjugate | AF CHEMICALS, LLC (US) | 2025-04-22 | — | — | US | disclosed |
| EP-4518919-A1 | HIGHLY ELASTIC MEDICAL SEALANTS FOR FLEXIBLE SOFT TISSUE | Ethicon, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| EP-4486394-A1 | FUNCTIONALIZED NANOCLUSTERS AND THEIR USE IN TREATING BACTERIAL INFECTIONS | The Board Of Trustees Of The Leland Stanford Junior University (US) | 2025-01-08 | — | — | EP | disclosed |
| US-12168081-B2 | Highly elastic medical sealants for flexible soft tissue | ETHICON, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| WO-2024184713-A1 | MEDICAL SEALANTS | ETHICON, INC. (US) | 2024-09-12 | — | — | WO | disclosed |
| US-20240299617-A1 | MEDICAL SEALANTS | ETHICON, INC. (US) | 2024-09-12 | — | — | US | disclosed |
| US-20240180150-A1 | Green Closed Loop Bio-waste Refining Process For Producing Smart Active Extracts and Delivery Systems for Their Application | CELLACURE LLC (US) | 2024-06-06 | — | — | US | disclosed |
| US-11998615-B2 | Functionalized nanoparticles and their use in treating bacterial infections | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-06-04 | — | — | US | disclosed |
| EP-3515476-B1 | FUSION COMPRISING A CELL PENETRATING PEPTIDE, A MULTIEPITOPE AND A TLR PEPTIDE AGONIST FOR TREATMENT OF CANCER | AMAL THERAPEUTICS SA (CH) | 2024-05-22 | — | — | EP | disclosed |
| US-11981752-B2 | Tumor associated monocyte/macrophage binding peptide and methods of use thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-05-14 | — | — | US | disclosed |
| US-20240150397-A1 | TARGETED DELIVERY SYSTEM AND METHODS OF USE THEREFOR | Sanford Burnham Prebys Medical Discovery Institute | 2024-05-09 | — | — | US | disclosed |
| WO-2024074940-A1 | FLOWABLE HYDROGEL HYDROCOLLOID COMPOSITE SEALANT | ETHICON, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| US-20240115758-A1 | FLOWABLE HYDROGEL HYDROCOLLOID COMPOSITE SEALANT | ETHICON, INC. | 2024-04-11 | — | — | US | disclosed |
| CN-111961134-B | Anti-blood dendritic cell antigen 2 antibody and application thereof | 比奥根MA公司 | 2024-04-05 | — | — | CN | disclosed |
| US-20240091315-A1 | XTEN CONJUGATE COMPOSITIONS AND METHODS OF MAKING SAME | AMUNIX PHARMACEUTICALS, INC. | 2024-03-21 | — | — | US | disclosed |
| WO-2024047445-A1 | BIODEGRADABLE LUNG SEALANTS | ETHICON, INC. (US) | 2024-03-07 | — | — | WO | disclosed |
| WO-2024047443-A1 | SEALANTS FOR TISSUE CLOSURE | ETHICON, INC. (US) | 2024-03-07 | — | — | WO | disclosed |
| US-20240066052-A1 | BIODEGRADABLE LUNG SEALANTS | ETHICON, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240066178-A1 | SEALANTS FOR TISSUE CLOSURE | ETHICON, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| EP-3429618-B1 | COMBINATION OF AN IMMUNE CHECKPOINT MODULATOR AND A COMPLEX COMPRISING A CELL PENETRATING PEPTIDE, A CARGO AND A TLR PEPTIDE AGONIST FOR USE IN MEDICINE | AMAL THERAPEUTICS SA (CH) | 2024-02-21 | — | — | EP | disclosed |
| EP-3693009-B1 | A NOVEL COMPLEX COMPRISING A CELL PENETRATING PEPTIDE, A CARGO AND A TLR PEPTIDE AGONIST FOR TREATMENT OF COLORECTAL CANCER | AMAL THERAPEUTICS SA (CH) | 2024-02-21 | — | — | EP | disclosed |
| US-20240043550-A1 | DE NOVO BINDING DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF | SUBDOMAIN, LLC | 2024-02-08 | — | — | US | disclosed |
| US-20230372267-A1 | AFFINITY MEDICANT CONJUGATE | Califia Pharma Inc. (US) | 2023-11-23 | — | — | US | disclosed |
| WO-2023213969-A1 | VIRAL-BINDING PROTEIN AND RELATED REAGENTS, ARTICLES, AND METHODS OF USE | JUNO THERAPEUTICS GMBH (DE) | 2023-11-09 | — | — | WO | disclosed |
| US-20230355831-A1 | Highly Elastic Medical Sealants for Flexible Soft Tissue | ETHICON, INC. | 2023-11-09 | — | — | US | disclosed |
| WO-2023214313-A1 | HIGHLY ELASTIC MEDICAL SEALANTS FOR FLEXIBLE SOFT TISSUE | ETHICON, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| US-20230310320-A1 | SOLUBLE MICROCARRIER, METHOD FOR MANUFACTURING AND METHOD OF USE THEREOF | NATIONAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY (TW) | 2023-10-05 | — | — | US | disclosed |
| CN-116801734-A | Green closed-loop biowaste refining process for producing intelligent active extracts and delivery system for its use | 塞拉治疗有限责任公司 | 2023-09-22 | — | — | CN | disclosed |
| CN-116744983-A | Bioabsorbable sealing powder | 西拉格国际有限公司 | 2023-09-12 | — | — | CN | disclosed |
| WO-2023164224-A1 | FUNCTIONALIZED NANOCLUSTERS AND THEIR USE IN TREATING BACTERIAL INFECTIONS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-08-31 | — | — | WO | disclosed |
| US-20230272351-A1 | COVID ASSAY CONTROLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-08-31 | — | — | US | disclosed |
| US-11723982-B2 | Methods of treating an ocular disease or disorder | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-15 | — | — | US | disclosed |
| EP-4195923-A1 | GREEN CLOSED LOOP BIO-WASTE REFINING PROCESS FOR PRODUCING SMART ACTIVE EXTRACTS AND DELIVERY SYSTEMS FOR THEIR APPLICATION | Cellacure LLC (US) | 2023-06-21 | — | — | EP | disclosed |
| US-20230149561-A1 | Functionalized Nanoparticles and Their Use in Treating Bacterial Infections | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-05-18 | — | — | US | disclosed |
| EP-2250278-B1 | METHODS AND COMPOSITIONS RELATED TO PEPTIDES AND PROTEINS WITH C-TERMINAL ELEMENTS | BURNHAM INSTITUTE FOR MEDICAL RES (US) | 2023-04-05 | — | — | EP | disclosed |
| US-20230053954-A1 | NON-WOVEN TEXTILE FROM UPCYCLED FRUIT AND VEGETABLE WASTE | BEYOND LEATHER MATERIALS APS (DK) | 2023-02-23 | — | — | US | disclosed |
| US-11576876-B2 | Affinity Medicant Conjugate | AF CHEMICALS, LLC (US) | 2023-02-14 | — | — | US | disclosed |
| US-20220339293-A1 | FUNCTIONALIZED NANOPARTICLES AND THEIR USE IN TREATING BACTERIAL INFECTIONS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2022-10-27 | — | — | US | disclosed |
| CN-115160438-A | Polypeptides comprising de novo binding domains and uses thereof | 苏伯多曼有限责任公司 | 2022-10-11 | — | — | CN | disclosed |
| US-11458212-B2 | Molecular imaging of cancer cells in vivo | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| US-20220265763-A1 | POLYPEPTIDE-POLYMER CONJUGATES AND METHODS OF USE THEREOF | UNIV CALIFORNIA (US) | 2022-08-25 | — | — | US | disclosed |
| US-20220227855-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF ANGIOGENESIS RELATED DISEASES | THE UNIVERSITY OF MASSACHUSETTS | 2022-07-21 | — | — | US | disclosed |
| EP-3386520-B1 | METHODS OF TREATING AN OCULAR DISEASE OR DISORDER | UNIV CALIFORNIA (US) | 2022-07-20 | — | — | EP | disclosed |
| US-11378572-B2 | Therapeutic agent for immune cell migration-caused disease and method for screening same | ZYMEDI CO., LTD. (KR) | 2022-07-05 | — | — | US | disclosed |
| US-20220195504-A1 | ANALYSIS OF MULTIPLE ANALYTES USING A SINGLE ASSAY | ILLUMINA, INC. | 2022-06-23 | — | — | US | disclosed |
| US-20220175941-A1 | METHODS AND COMPOSITIONS USING PEPTIDES AND PROTEINS WITH C-TERMINAL ELEMENTS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2022-06-09 | — | — | US | disclosed |
| US-20220175933-A1 | Novel Complex Comprising A Cell Penetrating Peptide, A Cargo And A TLR Peptide Agonist For Treatment Of Glioblastoma | AMAL THERAPEUTICS SA (CH) | 2022-06-09 | — | — | US | disclosed |
| US-11338027-B2 | Fusion comprising a cell penetrating peptide, a multi epitope and a TLR peptide agonist for treatment of cancer | AMAL THERAPEUTICS SA (CH) | 2022-05-24 | — | — | US | disclosed |
| EP-3996751-A1 | FUNCTIONALIZED NANOPARTICLES AND THEIR USE IN TREATING BACTERIAL INFECTIONS | The Board Of Trustees Of The Leland Stanford Junior University (US) | 2022-05-18 | — | — | EP | disclosed |
| EP-3994168-A1 | ANTIBODY TO LEPTIN RECEPTOR | Shanghaitech University (CN) | 2022-05-11 | — | — | EP | disclosed |
| US-20220118102-A1 | COMBINATION OF AN IMMUNE CHECKPOINT MODULATOR AND A COMPLEX COMPRISING A CELL PENETRATING PEPTIDE, A CARGO AND A TLR PEPTIDE AGONIST FOR USE IN MEDICINE | AMAL THERAPEUTICS SA (CH) | 2022-04-21 | — | — | US | disclosed |
| US-20220119450-A1 | BI-SPECIFIC EXTRACELLULAR MATRIX BINDING PEPTIDES AND METHODS OF USE THEREOF | UNIVERSITY OF TARTU (EE) | 2022-04-21 | — | — | US | disclosed |
| US-11291707-B2 | Polypeptide-polymer conjugates and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-05 | — | — | US | disclosed |
| US-20220096643-A1 | Acryloyloxyethylphosphorylcholine Containing Polymer Conjugates And Their Preparation | KODIAK SCIENCES INC (US) | 2022-03-31 | — | — | US | disclosed |
| US-11260133-B2 | Methods and compositions related to peptides and proteins with C-terminal elements | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2022-03-01 | — | — | US | disclosed |
| WO-2022036010-A1 | GREEN CLOSED LOOP BIO-WASTE REFINING PROCESS FOR PRODUCING SMART ACTIVE EXTRACTS AND DELIVERY SYSTEMS FOR THEIR APPLICATION | CELLACURE LLC (US) | 2022-02-17 | — | — | WO | disclosed |
| US-11241398-B2 | Affinity medicant conjugate | AF CHEMICALS, LLC (US) | 2022-02-08 | — | — | US | disclosed |
| US-20220031850-A1 | Complex Comprising A Cell Penetrating Peptide, A Cargo And A TLR Peptide Agonist For Treatment Of Colorectal Cancer | AMAL THERAPEUTICS SA (CH) | 2022-02-03 | — | — | US | disclosed |
| EP-3921329-A1 | BI-SPECIFIC EXTRACELLULAR MATRIX BINDING PEPTIDES AND METHODS OF USE THEREOF | University of Tartu (EE) | 2021-12-15 | — | — | EP | disclosed |
| EP-3903804-A1 | DE NOVO BINDING DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF | Subdomain, LLC (US) | 2021-11-03 | — | — | EP | disclosed |
| CN-113546178-A | Methods of treating ocular diseases or disorders | 加利福尼亚大学董事会 | 2021-10-26 | — | — | CN | disclosed |
| US-20210322518-A1 | XTEN CONJUGATE COMPOSITIONS AND METHODS OF MAKING SAME | AMUNIX PHARMACEUTICALS, INC. | 2021-10-21 | — | — | US | disclosed |
| US-11135182-B2 | Affinity medicant conjugates | AF CHEMICALS, LLC (US) | 2021-10-05 | — | — | US | disclosed |
| US-20210299063-A1 | AFFINITY MEDICANT CONJUGATE | AF CHEMICALS, LLC (US) | 2021-09-30 | — | — | US | disclosed |
| EP-3280433-B1 | DE NOVO BINDING DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF | SUBDOMAIN LLC (US) | 2021-09-15 | — | — | EP | disclosed |
| US-11091554-B2 | Binding molecules specific for HER3 and uses thereof | MEDLMMUNE, LLC (US) | 2021-08-17 | — | — | US | disclosed |
| CN-108472310-B | Conjugates for treating ocular diseases or disorders | 加利福尼亚大学董事会 | 2021-08-03 | — | — | CN | disclosed |
| US-11077212-B2 | Molecular imaging of cancer cells in vivo | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-20210230288-A1 | DE NOVO BINDING DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF | ARCELLX, INC. | 2021-07-29 | — | — | US | disclosed |
| US-11059718-B2 | Methods and compositions using peptides and proteins with C-terminal elements | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2021-07-13 | — | — | US | disclosed |
| US-11008397-B2 | De novo binding domain containing polypeptides and uses thereof | SUBDOMAIN, LLC (US) | 2021-05-18 | — | — | US | disclosed |
| US-20210085768-A1 | Fusion Comprising A Cell Penetrating Peptide, A Multi Epitope And A TLR Peptide Agonist For Treatment Of Cancer | AMAL THERAPEUTICS SA (CH) | 2021-03-25 | — | — | US | disclosed |
| US-10953073-B2 | XTEN conjugate compositions and methods of making same | AMUNIX PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-20210077425-A1 | AFFINITY MEDICANT CONJUGATE | AF CHEMICALS, LLC (US) | 2021-03-18 | — | — | US | disclosed |
| EP-3280432-B1 | DE NOVO BINDING DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF | SUBDOMAIN LLC (US) | 2021-03-10 | — | — | EP | disclosed |
| WO-2021000251-A1 | ANTIBODY TO LEPTIN RECEPTOR | SHANGHAITECH UNIVERSITY (CN) | 2021-01-07 | — | — | WO | disclosed |
| US-20210002381-A1 | DE NOVO BINDING DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF | SUBDOMAIN, LLC (US) | 2021-01-07 | — | — | US | disclosed |
| US-20200368365-A1 | COMPOUNDS AND COMPOSITIONS FOR TARGETING BRAIN INJURIES AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2020-11-26 | — | — | US | disclosed |
| US-10844375-B2 | Multimeric oligonucleotide compounds having non-nucleotide based cleavable linkers | TRANSLATE BIO MA, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200362046-A1 | DE NOVO BINDING DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF | SUBDOMAIN, LLC | 2020-11-19 | — | — | US | disclosed |
| US-20200268832-A1 | COMPOSITIONS FOR DELIVERY TO AND TREATMENT OF ATHEROSCLEROTIC PLAQUES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-08-27 | — | — | US | disclosed |
| CN-111565707-A | Devices and methods for delivering therapeutics | 森玛治疗公司 | 2020-08-21 | — | — | CN | disclosed |
| WO-2020161602-A1 | BI-SPECIFIC EXTRACELLULAR MATRIX BINDING PEPTIDES AND METHODS OF USE THEREOF | UNIVERSITY OF TARTU (EE) | 2020-08-13 | — | — | WO | disclosed |
| EP-3693009-A1 | A NOVEL COMPLEX COMPRISING A CELL PENETRATING PEPTIDE, A CARGO AND A TLR PEPTIDE AGONIST FOR TREATMENT OF COLORECTAL CANCER | Amal Therapeutics SA (CH) | 2020-08-12 | — | — | EP | disclosed |
| US-20200223934-A1 | DE NOVO BINDING DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF | SUBDOMAIN, LLC | 2020-07-16 | — | — | US | disclosed |
| US-20200190142-A1 | TUMOR ASSOCIATED MONOCYTE/MACROPHAGE BINDING PEPTIDE AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2020-06-18 | — | — | US | disclosed |
| US-10669311-B2 | Targeted delivery system and methods of use therefor | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-06-02 | — | — | US | disclosed |
| US-20200164093-A1 | Molecular Imaging of Cancer Cells In Vivo | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-05-28 | — | — | US | disclosed |
| US-10662248-B2 | De novo binding domain containing polypeptides and uses thereof | SUBDOMAIN LLC (US) | 2020-05-26 | — | — | US | disclosed |
| US-20200156935-A1 | METHODS AND COMPOSITIONS USING PEPTIDES AND PROTEINS WITH C-TERMINAL ELEMENTS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2020-05-21 | — | — | US | disclosed |
| US-10653797-B2 | Compounds and compositions for targeting brain injuries and methods of use thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-05-19 | — | — | US | disclosed |
| US-10647775-B2 | De novo binding domain containing polypeptides and uses thereof | SUBDOMAIN LLC (US) | 2020-05-12 | — | — | US | disclosed |
| US-20200141923-A1 | THERAPEUTIC AGENT FOR IMMUNE CELL MIGRATION-CAUSED DISEASE AND METHOD FOR SCREENING SAME | ZYMEDI CO., LTD. (KR) | 2020-05-07 | — | — | US | disclosed |
| EP-3628047-A1 | TUMOR ASSOCIATED MONOCYTE/MACROPHAGE BINDING PEPTIDE AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-04-01 | — | — | EP | disclosed |
| US-10590201-B2 | Nucleic acids encoding antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease | THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2020-03-17 | — | — | US | disclosed |
| EP-3608340-A1 | BINDING MOLECULES SPECIFIC FOR HER3 AND USES THEREOF | Medlmmune, LLC (US) | 2020-02-12 | — | — | EP | disclosed |
| EP-2895200-B1 | MULTIMERIC OLIGONUCLEOTIDE COMPOUNDS | TRANSLATE BIO MA INC (US) | 2019-11-06 | — | — | EP | disclosed |
| US-10406248-B2 | Molecular imaging of cancer cells in vivo | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-20190255165-A1 | Fusion Comprising A Cell Penetrating Peptide, A Multi Epitope And A TLR Peptide Agonist For Treatment Of Cancer | AMAL THERAPEUTICS SA (CH) | 2019-08-22 | — | — | US | disclosed |
| US-10370245-B2 | Methods and compositions using peptides and proteins with C-terminal elements | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2019-08-06 | — | — | US | disclosed |
| EP-3515476-A1 | FUSION COMPRISING A CELL PENETRATING PEPTIDE, A MULTI EPITOPE AND A TLR PEPTIDE AGONIST FOR TREATMENT OF CANCER | Amal Therapeutics SA (CH) | 2019-07-31 | — | — | EP | disclosed |
| EP-2797957-B1 | BINDING MOLECULES SPECIFIC FOR HER3 AND USES THEREOF | MEDIMMUNE LLC (US) | 2019-06-19 | — | — | EP | disclosed |
| US-20190175748-A1 | COMBINATION OF AN IMMUNE CHECKPOINT MODULATOR AND A COMPLEX COMPRISING A CELL PENETRATING PEPTIDE, A CARGO AND A TLR PEPTIDE AGONIST FOR USE IN MEDICINE | AMAL THERAPEUTICS SA (CH) | 2019-06-13 | — | — | US | disclosed |
| US-10272144-B2 | Compositions for and methods of treating and preventing targeting tumor associated carbohydrate antigens | BIOVENTURES, LLC (US) | 2019-04-30 | — | — | US | disclosed |
| US-20190083577-A1 | XTEN CONJUGATE COMPOSITIONS AND METHODS OF MAKING SAME | AMUNIX PHARMACEUTICALS, INC. | 2019-03-21 | — | — | US | disclosed |
| CN-109432438-A | ADC and its preparation method and application based on H2-18 antibody coupling drug doxorubicin hydrochloride | 上海健康医学院 | 2019-03-08 | — | — | CN | disclosed |
| US-20190040143-A1 | BINDING MOLECULES SPECIFIC FOR HER3 AND USES THEREOF | MEDIMMUNE, LLC (US) | 2019-02-07 | — | — | US | disclosed |
| EP-3429618-A1 | COMBINATION OF AN IMMUNE CHECKPOINT MODULATOR AND A COMPLEX COMPRISING A CELL PENETRATING PEPTIDE, A CARGO AND A TLR PEPTIDE AGONIST FOR USE IN MEDICINE | Amal Therapeutics SA (CH) | 2019-01-23 | — | — | EP | disclosed |
| US-10172953-B2 | XTEN conjugate compositions and methods of making same | AMUNIX OPERATING INC. (US) | 2019-01-08 | — | — | US | disclosed |
| EP-3406347-A2 | XTEN CONJUGATE COMPOSITIONS AND METHODS OF MAKING SAME | Amunix Operating Inc. (US) | 2018-11-28 | — | — | EP | disclosed |
| US-10139394-B2 | Method for controlling cancer metastasis or cancer cell migration by modulating the cellular level of lysyl tRNA synthetase | MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) | 2018-11-27 | — | — | US | disclosed |
| WO-2018204392-A1 | TUMOR ASSOCIATED MONOCYTE/MACROPHAGE BINDING PEPTIDE AND METHODS OF USE THEREOF | STANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE (US) | 2018-11-08 | — | — | WO | disclosed |
| US-20180303898-A1 | COMPOSITIONS FOR DELIVERY TO AND TREATMENT OF ATHEROSCLEROTIC PLAQUES | Sanford Burnham Prebys Medical Discovery Institute (US) | 2018-10-25 | — | — | US | disclosed |
| US-20180296696-A1 | COMPOUNDS AND COMPOSITIONS FOR TARGETING BRAIN INJURIES AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2018-10-18 | — | — | US | disclosed |
| EP-3388534-A1 | COMPOSITIONS FOR TREATING STOMACHAL AND OESOPHAGEAL CANCER CELLS | Thomas Jefferson University (US) | 2018-10-17 | — | — | EP | disclosed |
| EP-3028048-B1 | COMPOSITIONS FOR TREATING AND PREVENTING CANCER TARGETING TUMOR ASSOCIATED CARBOHYDRATE ANTIGENS | BIOVENTURES LLC (US) | 2018-09-26 | — | — | EP | disclosed |
| US-20180251563-A1 | DE NOVO BINDING DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF | SUBDOMAIN, LLC (US) | 2018-09-06 | — | — | US | disclosed |
| US-20180251521-A1 | DE NOVO BINDING DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF | SUBDOMAIN, LLC (US) | 2018-09-06 | — | — | US | disclosed |
| US-20180244720-A1 | TARGETED DELIVERY SYSTEM AND METHODS OF USE THEREFOR | Sanford Burnham Prebys Medical Discovery Institute (US) | 2018-08-30 | — | — | US | disclosed |
| EP-2819788-B1 | XTEN CONJUGATE COMPOSITIONS AND METHODS OF MAKING SAME | AMUNIX OPERATING INC (US) | 2018-08-22 | — | — | EP | disclosed |
| US-10040857-B2 | Binding molecules specific for HER3 and uses thereof | MEDIMMUNE, LLC (US) | 2018-08-07 | — | — | US | disclosed |
| US-20180209983-A1 | DE NOVO BINDING DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF | SUBDOMAIN, LLC (US) | 2018-07-26 | — | — | US | disclosed |
| CN-108279311-A | The quickly self assembly immuno-sandwich impedance transducer of detection Alzheimer marker protein Tau | 杭州电子科技大学 | 2018-07-13 | — | — | CN | disclosed |
| US-20180186888-A1 | ANTIBODIES THAT BIND TO TL1A AND METHODS OF TREATING INFLAMMATORY OR AUTOIMMUNE DISEASE COMPRISING ADMINISTERING SUCH ANTIBODIES | THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES | 2018-07-05 | — | — | US | disclosed |
| US-20180133338-A1 | A Novel Complex Comprising A Cell Penetrating Peptide, A Cargo And A TLR Peptide Agonist For Treatment Of Colorectal Cancer | AMAL THERAPEUTICS SA (CH) | 2018-05-17 | — | — | US | disclosed |
| US-20180133339-A1 | A Novel Complex Comprising A Cell Penetrating Peptide, A Cargo And A TLR Peptide Agonist For Treatment Of Glioblastoma | AMAL THERAPEUTICS SA (CH) | 2018-05-17 | — | — | US | disclosed |
| US-20180133327-A1 | Cell Penetrating Peptides and Complexes Comprising the Same | AMAL THERAPEUTICS SA (CH) | 2018-05-17 | — | — | US | disclosed |
| US-20180125988-A1 | TARGETED XTEN CONJUGATE COMPOSITIONS AND METHODS OF MAKING SAME | AMUNIX OPERATING INC. | 2018-05-10 | — | — | US | disclosed |
| EP-2949762-B1 | COMPOSITIONS FOR TREATING STOMACHAL AND OESOPHAGEAL CANCER CELLS | UNIV JEFFERSON (US) | 2018-05-09 | — | — | EP | disclosed |
| US-20180117175-A1 | TEMPLATED NANOCONJUGATES | NORTHWESTERN UNIVERSITY | 2018-05-03 | — | — | US | disclosed |
| EP-3313447-A2 | COMPOSITIONS FOR DELIVERY TO AND TREATMENT OF ATHEROSCLEROTIC PLAQUES | Sanford Burnham Prebys Medical Discovery Institute (US) | 2018-05-02 | — | — | EP | disclosed |
| WO-2018055060-A1 | FUSION COMPRISING A CELL PENETRATING PEPTIDE, A MULTI EPITOPE AND A TLR PEPTIDE AGONIST FOR TREATMENT OF CANCER | AMAL THERAPEUTICS SA (CH) | 2018-03-29 | — | — | WO | disclosed |
| US-9896511-B2 | Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2018-02-20 | — | — | US | disclosed |
| EP-3280433-A1 | DE NOVO BINDING DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF | Subdomain LLC (US) | 2018-02-14 | — | — | EP | disclosed |
| EP-3280432-A1 | DE NOVO BINDING DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF | Subdomain LLC (US) | 2018-02-14 | — | — | EP | disclosed |
| US-20180030444-A1 | MULTIMERIC OLIGONUCLEOTIDE COMPOUNDS HAVING NON-NUCLEOTIDE BASED CLEAVABLE LINKERS | TRANSLATE BIO MA, INC. (US) | 2018-02-01 | — | — | US | disclosed |
| EP-3270955-A1 | A NOVEL COMPLEX COMPRISING A CELL PENETRATING PEPTIDE, A CARGO AND A TLR PEPTIDE AGONIST FOR TREATMENT OF COLORECTAL CANCER | Amal Therapeutics SA (CH) | 2018-01-24 | — | — | EP | disclosed |
| EP-3270957-A1 | A NOVEL COMPLEX COMPRISING A CELL PENETRATING PEPTIDE, A CARGO AND A TLR PEPTIDE AGONIST FOR TREATMENT OF GLIOBLASTOMA | Amal Therapeutics SA (CH) | 2018-01-24 | — | — | EP | disclosed |
| EP-3270954-A1 | A NOVEL COMPLEX COMPRISING A CELL PENETRATING PEPTIDE, A CARGO AND A TLR PEPTIDE AGONIST | Amal Therapeutics SA (CH) | 2018-01-24 | — | — | EP | disclosed |
| EP-1988910-B1 | ACRYLOYLOXYETHYLPHOSPHORYLCHOLINE CONTAINING POLYMER CONJUGATES AND THEIR PREPARATION | KODIAK SCIENCES INC (US) | 2017-12-06 | — | — | EP | disclosed |
| US-9790494-B2 | Multimeric oligonucleotide compounds having non-nucleotide based cleavable linkers | TRANSLATE BIO MA, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9783576-B2 | Compositions and methods for targeted endometriosis treatment | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2017-10-10 | — | — | US | disclosed |
| EP-3222142-A1 | ACRYLOYLOXYETHYLPHOSPHORYLCHOLINE CONTAINING POLYMER CONJUGATES AND THEIR PREPARATION | Kodiak Sciences Inc. (US) | 2017-09-27 | — | — | EP | disclosed |
| US-20170267543-A1 | TRANSITION METAL DICHALCOGENIDE AEROGELS AND METHODS OF PREPARATION AND USE | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2017-09-21 | — | — | US | disclosed |
| WO-2017157964-A1 | COMBINATION OF AN IMMUNE CHECKPOINT MODULATOR AND A COMPLEX COMPRISING A CELL PENETRATING PEPTIDE, A CARGO AND A TLR PEPTIDE AGONIST FOR USE IN MEDICINE | AMAL THERAPEUTICS SA (CH) | 2017-09-21 | — | — | WO | disclosed |
| EP-3218390-A2 | TARGETED XTEN CONJUGATE COMPOSITIONS AND METHODS OF MAKING SAME | Amunix Operating Inc. (US) | 2017-09-20 | — | — | EP | disclosed |
| US-9757475-B2 | Templated nanoconjugates | NORTHWESTERN UNIVERSITY (US) | 2017-09-12 | — | — | US | disclosed |
| US-20170246236-A1 | METHODS AND COMPOSITIONS FOR ENHANCED DELIVERY OF COMPOUNDS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2017-08-31 | — | — | US | disclosed |
| EP-2758775-B1 | NOVEL USE OF LEUCYL TRNA SYNTHETASE | MEDICINAL BIOCONVERGENCE RES CT (KR) | 2017-08-16 | — | — | EP | disclosed |
| US-20170189550-A1 | SILICON PARTICLES TARGETING TUMOR CELLS | PHILIPPS UNIVERSITAET MARBURG (DE) | 2017-07-06 | — | — | US | disclosed |
| EP-2152736-B1 | COMPLEMENT FACTOR H-DERIVED SHORT CONSENSUS REPEAT-ANTIBODY CONSTRUCTS | LYSOMAB GMBH (AT) | 2017-07-05 | — | — | EP | disclosed |
| EP-2268664-B1 | DOC1 COMPOSITIONS AND METHODS FOR TREATING CANCER | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPT OF HEALTH (US) | 2017-05-24 | — | — | EP | disclosed |
| US-20170108489-A1 | METHOD FOR CONTROLLING CANCER METASTASIS OR CANCER CELL MIGRATION BY MODULATING THE CELLULAR LEVEL OF LYSYL TRNA SYNTHETASE | MEDICINAL BIOCONVERGENCE RESEARCH CENTER | 2017-04-20 | — | — | US | disclosed |
| EP-3145551-A1 | SILICON PARTICLES TARGETING TUMOR CELLS | Universitat Rovira I Virgili (ES) | 2017-03-29 | — | — | EP | disclosed |
| WO-2017040976-A1 | COMPOUNDS AND COMPOSITIONS FOR TARGETING BRAIN INJURIES AND METHODS OF USE THEREOF | RUOSLAHTI ERKKI (US) | 2017-03-09 | — | — | WO | disclosed |
| EP-2766730-B1 | METHOD FOR SCREENING AN AGENT PREVENTING OR TREATING CANCER USING GLYCYL-TRNA SYNTHETASE AND CADHERIN | MEDICINAL BIOCONVERGENCE RES CT (KR) | 2017-03-01 | — | — | EP | disclosed |
| US-20170049869-A1 | Compositions and Methods for Identifying and Targeting Cancer Cells of Alimentary Canal Origin | THOMAS JEFFERSON UNIVERSITY | 2017-02-23 | — | — | US | disclosed |
| WO-2016210423-A9 | COMPOSITIONS FOR DELIVERY TO AND TREATMENT OF ATHEROSCLEROTIC PLAQUES | Sanford Burnham Prebys Medical Discovery Institute (US) | 2017-02-02 | — | — | WO | disclosed |
| WO-2016210423-A2 | COMPOSITIONS FOR DELIVERY TO AND TREATMENT OF ATHEROSCLEROTIC PLAQUES | Sanford Burnham Prebys Medical Discovery Institute (US) | 2016-12-29 | — | — | WO | disclosed |
| US-20160377599-A1 | LIVER INFECTION | CN BIO INNOVATIONS LIMITED (GB) | 2016-12-29 | — | — | US | disclosed |
| US-9511085-B2 | Method for controlling cancer metastasis or cancer cell migration by modulating the cellular level of lysyl tRNA synthetase | MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) | 2016-12-06 | — | — | US | disclosed |
| WO-2016172515-A1 | TARGETED DELIVERY SYSTEM AND METHODS OF USE THEREFOR | Sanford Burnham Prebys Medical Discovery Institute (US) | 2016-10-27 | — | — | WO | disclosed |
| WO-2016164369-A2 | DE NOVO BINDING DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF | SUBDOMAIN, LLC (US) | 2016-10-13 | — | — | WO | disclosed |
| WO-2016164305-A1 | DE NOVO BINDING DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF | SUBDOMAIN, LLC (US) | 2016-10-13 | — | — | WO | disclosed |
| WO-2016164308-A1 | DE NOVO BINDING DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF | SUBDOMAIN, LLC (US) | 2016-10-13 | — | — | WO | disclosed |
| US-20160289334-A2 | Compositions and Methods of Treating Tumors | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-10-06 | — | — | US | disclosed |
| WO-2016146261-A1 | COMBINATION OF AN IMMUNE CHECKPOINT MODULATOR AND A COMPLEX COMPRISING A CELL PENETRATING PEPTIDE, A CARGO AND A TLR PEPTIDE AGONIST FOR USE IN MEDICINE | AMAL THERAPEUTICS SA (CH) | 2016-09-22 | — | — | WO | disclosed |
| WO-2016146259-A1 | A NOVEL COMPLEX COMPRISING A CELL PENETRATING PEPTIDE, A CARGO AND A TLR PEPTIDE AGONIST FOR TREATMENT OF GLIOBLASTOMA | AMAL THERAPEUTICS SA (CH) | 2016-09-22 | — | — | WO | disclosed |
| WO-2016146262-A1 | A NOVEL COMPLEX COMPRISING A CELL PENETRATING PEPTIDE, A CARGO AND A TLR PEPTIDE AGONIST FOR TREATMENT OF COLORECTAL CANCER | AMAL THERAPEUTICS SA (CH) | 2016-09-22 | — | — | WO | disclosed |
| WO-2016146143-A1 | CELL PENETRATING PEPTIDES AND COMPLEXES COMPRISING THE SAME | AMAL THERAPEUTICS SA (CH) | 2016-09-22 | — | — | WO | disclosed |
| WO-2016146260-A1 | A NOVEL COMPLEX COMPRISING A CELL PENETRATING PEPTIDE, A CARGO AND A TLR PEPTIDE AGONIST | AMAL THERAPEUTICS SA (CH) | 2016-09-22 | — | — | WO | disclosed |
| US-9435807-B2 | Use of leucyl tRNA synthetase | MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) | 2016-09-06 | — | — | US | disclosed |
| US-20160237162-A1 | BINDING MOLECULES SPECIFIC FOR HER3 AND USES THEREOF | MEDIMMUNE, LLC (US) | 2016-08-18 | — | — | US | disclosed |
| US-20160206747-A1 | Templated Nanoconjugates | NORTHWESTERN UNIVERSITY | 2016-07-21 | — | — | US | disclosed |
| EP-2334791-B1 | METHOD FOR CONTROLLING CANCER METASTASIS OR CANCER CELL MIGRATION BY MODULATING THE CELLULAR LEVEL OF LYSYL TRNA SYNTHETASE | MEDICINAL BIOCONVERGENCE RES CT (KR) | 2016-07-13 | — | — | EP | disclosed |
| US-20160195533-A1 | METHOD FOR SCREENING EMT INHIBITOR | MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) | 2016-07-07 | — | — | US | disclosed |
| US-20160184415-A1 | COMPOSITIONS FOR AND METHODS OF TREATING AND PREVENTING TARGETING TUMOR ASSOCIATED CARBOHYDRATE ANTIGENS | BIOVENTURES, LLC | 2016-06-30 | — | — | US | disclosed |
| US-20160176935-A1 | FILIP1L compositions and methods for treating cancer | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2016-06-23 | — | — | US | disclosed |
| US-20160159913-A1 | BINDING MOLECULES SPECIFIC FOR HER3 AND USES THEREOF | MEDIMMUNE LLC (US) | 2016-06-09 | — | — | US | disclosed |
| EP-3028048-A1 | COMPOSITIONS FOR AND METHODS OF TREATING AND PREVENTING CANCER TARGETING TUMOR ASSOCIATED CARBOHYDRATE ANTIGENS | Board of Trustees of the University of Arkansas (US) | 2016-06-08 | — | — | EP | disclosed |
| EP-2445536-B1 | METHODS AND COMPOSITIONS USING PEPTIDES AND PROTEINS WITH C-TERMINAL ELEMENTS | BURNHAM INST MEDICAL RESEARCH (US) | 2016-06-08 | — | — | EP | disclosed |
| US-20160145308-A1 | Compositions and Methods for Targeted Endometriosis Treatment | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2016-05-26 | — | — | US | disclosed |
| WO-2016077505-A2 | TARGETED XTEN CONJUGATE COMPOSITIONS AND METHODS OF MAKING SAME | AMUNIX OPERATING INC. (US) | 2016-05-19 | — | — | WO | disclosed |
| EP-2497768-B1 | NOVEL 2, 4-PYRIMIDINE DERIVATIVES AND USE THEREOF | SNU R&DB FOUNDATION (KR) | 2016-04-20 | — | — | EP | disclosed |
| CN-105452295-A | Anti-blood dendritic cell antigen 2 antibodies and uses thereof | BIOGEN IDEC INC | 2016-03-30 | — | — | CN | disclosed |
| US-20160083478-A1 | Compositions and Methods of Treating Tumors | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160053007-A1 | ANTIBODIES THAT BIND TO TL1A AND METHODS OF TREATING INFLAMMATORY OR AUTOIMMUNE DISEASE COMPRISING ADMINISTERING SUCH ANTIBODIES | THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES | 2016-02-25 | — | — | US | disclosed |
| CN-102666879-B | Templated nanometer conjugate | NORTHWEST UNIVERSITY (US) | 2016-02-24 | — | — | CN | disclosed |
| CN-105267983-A | iNGR-modified targeted self-assembly RNAi nano drug delivery system for brain glioma and preparation method of system | UNIV FUDAN | 2016-01-27 | — | — | CN | disclosed |
| CN-102782159-B | Compositions and methods for sequencing nucleic acids | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (CN) | 2016-01-20 | — | — | CN | disclosed |
| CN-102869384-B | Use the method and composition with the peptides and proteins of C-end element | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2016-01-13 | — | — | CN | disclosed |
| US-9220775-B2 | Binding molecules specific for HER3 and uses thereof | MEDIMMUNE LLC (US) | 2015-12-29 | — | — | US | disclosed |
| EP-2949762-A1 | COMPOSITIONS FOR TREATING AND IMAGING STOMACHAL AND OESOPHAGEAL CANCER CELLS | Thomas Jefferson University (US) | 2015-12-02 | — | — | EP | disclosed |
| WO-2015177340-A1 | SILICON PARTICLES TARGETING TUMOR CELLS | UNIVERSITAT ROVIRA I VIRGILI (ES) | 2015-11-26 | — | — | WO | disclosed |
| EP-2946793-A1 | Silicon particles targeting tumor cells | Universitat Rovira I Virgili (ES) | 2015-11-25 | — | — | EP | disclosed |
| US-20150315585-A1 | MULTIMERIC OLIGONUCLEOTIDE COMPOUNDS HAVING NON-NUCLEOTIDE BASED CLEAVABLE LINKERS | RANA THERAPEUTICS, INC. (US) | 2015-11-05 | — | — | US | disclosed |
| US-20150315586-A1 | METHODS OF DELIVERING MULTIPLE TARGETING OLIGONUCLEOTIDES TO A CELL USING NON-NUCLEOTIDE BASED CLEAVABLE LINKERS | RANA THERAPEUTICS, INC. (US) | 2015-11-05 | — | — | US | disclosed |
| US-20150290362-A1 | HYBRID FIBRIN-MICROGEL CONSTRUCTS FOR TISSUE REPAIR AND REGENERATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-15 | — | — | US | disclosed |
| EP-2916876-A1 | METHODS AND COMPOSITIONS FOR WOUND HEALING | Imbed Biosciences, Inc. (US) | 2015-09-16 | — | — | EP | disclosed |
| US-20150247141-A1 | MULTIMERIC OLIGONUCLEOTIDE COMPOUNDS | RANA THERAPEUTICS, INC. (US) | 2015-09-03 | — | — | US | disclosed |
| EP-2230320-B1 | Compositions for treating and imaging stomachal and oesophageal cancer cells | UNIV JEFFERSON (US) | 2015-07-01 | — | — | EP | disclosed |
| US-9068003-B2 | Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2015-06-30 | — | — | US | disclosed |
| WO-2015048008-A2 | BINDING MOLECULES SPECIFIC FOR HER3 AND USES THEREOF | MEDIMMUNE, LLC (US) | 2015-04-02 | — | — | WO | disclosed |
| US-20150079007-A1 | TUNABLE MULTIMODAL NANOPARTICLES AND METHODS OF USE THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2015-03-19 | — | — | US | disclosed |
| US-8951971-B2 | Lymphatic zip codes in tumors and pre-malignant lesions | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2015-02-10 | — | — | US | disclosed |
| US-20150037359-A1 | XTEN CONJUGATE COMPOSITIONS AND METHODS OF MAKING SAME | Amunix Operating, Inc. (US) | 2015-02-05 | — | — | US | disclosed |
| WO-2015017734-A1 | COMPOSITIONS FOR AND METHODS OF TREATING AND PREVENTING CANCER TARGETING TUMOR ASSOCIATED CARBOHYDRATE ANTIGENS | BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2015-02-05 | — | — | WO | disclosed |
| US-8946168-B2 | Compositions and methods for identifying and targeting cancer cells of alimentary canal origin | THOMAS JEFFERSON UNIVERSITY (US) | 2015-02-03 | — | — | US | disclosed |
| US-8940888-B2 | Hydrazido derivatives of hyaluronic acid | PROCHON BIOTECH LTD. (US) | 2015-01-27 | — | — | US | disclosed |
| CN-104274834-A | Environment-sensitive tumor-targeting polymer micelle and preparation method thereof | UNIV FUDAN | 2015-01-14 | — | — | CN | disclosed |
| US-20150010551-A1 | Compositions and Methods of Treating Tumors | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2015-01-08 | — | — | US | disclosed |
| EP-2819788-A2 | XTEN CONJUGATE COMPOSITIONS AND METHODS OF MAKING SAME | Amunix Operating Inc. (US) | 2015-01-07 | — | — | EP | disclosed |
| WO-2014201118-A2 | COMPOSITIONS AND METHODS FOR TARGETED ENDOMETRIOSIS TREATMENT | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2014-12-18 | — | — | WO | disclosed |
| US-20140363429-A1 | BINDING MOLECULES SPECIFIC FOR HER3 AND USES THEREOF | MEDIMMUNE LLC (US) | 2014-12-11 | — | — | US | disclosed |
| EP-2797957-A1 | BINDING MOLECULES SPECIFIC FOR HER3 AND USES THEREOF | MedImmune, LLC (US) | 2014-11-05 | — | — | EP | disclosed |
| EP-2766730-A1 | METHOD FOR SCREENING AN AGENT PREVENTING OR TREATING CANCER USING GLYCYL-TRNA SYNTHETASE AND CADHERIN | Medicinal Bioconvergence Research Center (KR) | 2014-08-20 | — | — | EP | disclosed |
| US-20140220106-A1 | LYMPHATIC ZIP CODES IN TUMORS AND PRE-MALIGNANT LESIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140161725-A1 | Molecular Imaging of Cancer Cells In Vivo | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2014-06-12 | — | — | US | disclosed |
| WO-2014074503-A1 | METHODS AND COMPOSITIONS FOR WOUND HEALING | IMBED BIOSCIENCES, INC. (US) | 2014-05-15 | — | — | WO | disclosed |
| EP-2722060-A2 | Guanylyl cyclase C ligands | Thomas Jefferson University (US) | 2014-04-23 | — | — | EP | disclosed |
| EP-2709664-A1 | BLOCKADE OF TL1A-DR3 INTERACTIONS TO AMELIORATE T CELL MEDIATED DISEASE PATHOLOGY AND ANTIBODIES THEREOF | The Government of the United States, as represented by The Secretary of the Department of Health and Human Services (US) | 2014-03-26 | — | — | EP | disclosed |
| US-20140005141-A1 | HYDRAZIDO DERIVATIVES OF HYALURONIC ACID | BIO-TECHNOLOGY GENERAL (ISRAEL) LTD. (IL) | 2014-01-02 | — | — | US | disclosed |
| EP-1781339-B1 | Guanylyl cyclase C ligands | UNIV JEFFERSON (US) | 2013-12-25 | — | — | EP | disclosed |
| WO-2013159092-A1 | TUNABLE MULTIMODAL NANOPARTICLES AND METHODS OF USE THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2013-10-24 | — | — | WO | disclosed |
| US-8563682-B2 | Guanylylcyclase C ligands | THOMAS JEFFERSON UNIVERSITY (US) | 2013-10-22 | — | — | US | disclosed |
| US-8536132-B2 | Lymphatic zip codes in tumors and pre-malignant lesions | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2013-09-17 | — | — | US | disclosed |
| WO-2013130684-A1 | XTEN-FOLATE CONJUGATE COMPOSITIONS AND METHODS OF MAKING SAME | AMUNIX OPERATING INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| WO-2013130683-A2 | XTEN CONJUGATE COMPOSITIONS AND METHODS OF MAKING SAME | AMUNIX OPERATING INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| US-20130217635-A1 | NOVEL USE OF ERYTHROID DIFFERENTIATION REGULATOR 1 AS AN AGENT FOR TREATING CANCER | IL-YANG PHARM. CO., LTD (KR) | 2013-08-22 | — | — | US | disclosed |
| US-8513380-B2 | Peptides for binding fibrinogen and fibrin | GEORGIA TECH RESEARCH CORPORATION (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513197-B2 | Ganglioside epitopes for treating Guillain-Barre syndrome | GEORGIA REGENTS UNIVERSITY (US) | 2013-08-20 | — | — | US | disclosed |
| US-20130204069-A1 | Compositions and Methods of Treating Tumors | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2013-08-08 | — | — | US | disclosed |
| US-8501912-B2 | Filipil compositions and methods for treating cancer | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2013-08-06 | — | — | US | disclosed |
| EP-1991587-B1 | HYDRAZIDO DERIVATIVES OF HYALURONIC ACID | PROCHON BIOTECH LTD (IL) | 2013-07-24 | — | — | EP | disclosed |
| WO-2013078191-A1 | BINDING MOLECULES SPECIFIC FOR HER3 AND USES THEREOF | MEDIMMUNE, LLC (US) | 2013-05-30 | — | — | WO | disclosed |
| US-20130129619-A1 | Molecular Imaging of Cancer Cells In Vivo | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130115170-A1 | GM1-LIKE PEPTIDES AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-05-09 | — | — | US | disclosed |
| US-8435947-B2 | Endothelial nitric oxide synthase antagonists and uses thereof for inhibiting oxygen toxicity | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC. (US) | 2013-05-07 | — | — | US | disclosed |
| WO-2013055101-A1 | METHOD FOR SCREENING AN AGENT PREVENTING OR TREATING CANCER USING GLYCYL-TRNA SYNTHETASE AND CADHERIN | MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) | 2013-04-18 | — | — | WO | disclosed |
| WO-2013036543-A2 | MOLECULAR IMAGING OF CANCER CELLS IN VIVO | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2013-03-14 | — | — | WO | disclosed |
| US-20130052154-A1 | Compositions and Methods for the Treatment of Lung Inflammation | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2013-02-28 | — | — | US | disclosed |
| EP-2555802-A1 | METHODS AND COMPOSITIONS FOR ENHANCED DELIVERY OF COMPOUNDS | Sanford-Burnham Medical Research Institute (US) | 2013-02-13 | — | — | EP | disclosed |
| WO-2013019745-A1 | METHODS AND COMPOSITIONS FOR GENETICALLY MODIFIYING CELLS | Georgia Health Sciences University (US) | 2013-02-07 | — | — | WO | disclosed |
| EP-2550008-A2 | NOVEL USE OF ERYTHROID DIFFERENTIATION REGULATOR 1 AS AN AGENT FOR TREATING CANCER | Industry-academic Cooperation Foundation, Sookmyunng Women's University (KR) | 2013-01-30 | — | — | EP | disclosed |
| CN-102869384-A | Methods and compositions using peptides and proteins with C-terminal elements | BURNHAM INST MEDICAL RESEARCH | 2013-01-09 | — | — | CN | disclosed |
| US-20120321552-A1 | Compositions and Methods for Identifying and Targeting Cancer Cells of Alimentary Canal Origin | THOMAS JEFFERSON UNIVERSITY (US) | 2012-12-20 | — | — | US | disclosed |
| WO-2012162490-A1 | NANOZYME COMPOSITIONS AND METHODS OF SYNTHESIS AND USE THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2012-11-29 | — | — | WO | disclosed |
| WO-2012161856-A1 | BLOCKADE OF TL1A-DR3 INTERACTIONS TO AMELIORATE T CELL MEDIATED DISEASE PATHOLOGY AND ANTIBODIES THEREOF | GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-11-29 | — | — | WO | disclosed |
| US-20120294850-A1 | Ganglioside Epitopes For Treating Guillain-Barre Syndrome | Georgia Health Sciences University | 2012-11-22 | — | — | US | disclosed |
| CN-102782159-A | Compositions and methods for sequencing nucleic acids | IND TECH RES INST | 2012-11-14 | — | — | CN | disclosed |
| US-20120263718-A1 | BLOCKADE OF TL1A-DR3 INTERACTIONS TO AMELIORATE T CELL MEDIATED DISEASE PATHOLOGY AND ANTIBODIES THEREOF | GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY. | 2012-10-18 | — | — | US | disclosed |
| EP-2497768-A2 | NOVEL 2, 4-PYRIMIDINE DERIVATIVES AND USE THEREOF | SNU R&DB Foundation (KR) | 2012-09-12 | — | — | EP | disclosed |
| WO-2012118778-A1 | TRUNCATED CAR PEPTIDES AND METHODS AND COMPOSITIONS USING TRUNCATED CAR PEPTIDES | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2012-09-07 | — | — | WO | disclosed |
| EP-2492285-A1 | Hydrazido derivatives of hyaluronic acid | ProChon Biotech Ltd. (IL) | 2012-08-29 | — | — | EP | disclosed |
| US-8236765-B2 | Ganglioside epitopes for treating guillain-barre syndrome | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC. (US) | 2012-08-07 | — | — | US | disclosed |
| EP-2478766-A2 | Targeting host proteinases as a therapeutic strategy against viral and bacterial pathogens | Burnham Institute for Medical Research (US) | 2012-07-25 | — | — | EP | disclosed |
| US-20120114682-A1 | PEPTIDES FOR BINDING FIBRINOGEN AND FIBRIN | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-05-10 | — | — | US | disclosed |
| US-20120115785-A1 | ENDOTHELIAL NITRIC OXIDE SYNTHASE ANTAGONISTS AND USES THEREOF FOR INHIBITING OXYGEN TOXICITY | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC | 2012-05-10 | — | — | US | disclosed |
| EP-2445536-A1 | METHODS AND COMPOSITIONS USING PEPTIDES AND PROTEINS WITH C-TERMINAL ELEMENTS | Burnham Institute for Medical Research (US) | 2012-05-02 | — | — | EP | disclosed |
| WO-2011118981-A9 | NOVEL USE OF ERYTHROID DIFFERENTIATION REGULATOR 1 AS AN AGENT FOR TREATING CANCER | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, SOOKMYUNG WOMEN'S UNIVERSITY (KR) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012027493-A1 | MOLECULAR IMAGING OF CANCER CELLS IN VIVO | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| WO-2011127405-A9 | METHODS AND COMPOSITIONS FOR ENHANCED DELIVERY OF COMPOUNDS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011127405-A1 | METHODS AND COMPOSITIONS FOR ENHANCED DELIVERY OF COMPOUNDS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2011-10-13 | — | — | WO | disclosed |
| EP-2334791-A1 | METHOD FOR CONTROLLING CANCER METASTASIS OR CANCER CELL MIGRATION BY MODULATING THE CELLULAR LEVEL OF LYSYL TRNA SYNTHETASE | Seoul National University Industry Foundation (KR) | 2011-06-22 | — | — | EP | disclosed |
| WO-2011011631-A2 | NUCLEIC ACID DELIVERY VEHICLES | ZALIPSKY SAMUEL (US) | 2011-01-27 | — | — | WO | disclosed |
| US-20100322862-A1 | METHODS AND COMPOSITIONS USING PEPTIDES AND PROTEINS WITH C-TERMINAL ELEMENTS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-12-23 | — | — | US | disclosed |
| EP-2258724-A1 | Modulating immune responses using multimerized anti-CD83 antibodies | Celltech R & D, Inc. (US) | 2010-12-08 | — | — | EP | disclosed |
| US-20100297160-A1 | High Molecular Weight Amyloid Beta As a Carrier for the Oral Delivery of Vaccine Antigens | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC. | 2010-11-25 | — | — | US | disclosed |
| EP-2250278-A2 | METHODS AND COMPOSITIONS RELATED TO PEPTIDES AND PROTEINS WITH C-TERMINAL ELEMENTS CROSS-REFERENCE TO RELATED APPLICATIONS | Burnham Institute for Medical Research (US) | 2010-11-17 | — | — | EP | disclosed |
| US-7829276-B2 | Methods of using CRCA-1 as a stomach and esophageal cancer marker | THOMAS JEFFERSON UNIVERSITY (US) | 2010-11-09 | — | — | US | disclosed |
| EP-2230320-A1 | Compositions and methods for identifying and targeting cancer cells of alimentary canal origin | Thomas Jefferson University (US) | 2010-09-22 | — | — | EP | disclosed |
| EP-2227567-A2 | SENSORS FOR MEASURING CONTAMINANTS | ECI Biotech Inc. (US) | 2010-09-15 | — | — | EP | disclosed |
| EP-1572976-B1 | MODULATING IMMUNE RESPONSES | CELLTECH R & D INC (US) | 2010-09-15 | — | — | EP | disclosed |
| EP-2215481-A1 | DIAGNOSTIC USE OF INDIVIDUAL MOLECULAR FORMS OF A BIOMARKER | Bioporto Diagnostics A/s (DK) | 2010-08-11 | — | — | EP | disclosed |
| EP-2208737-A1 | Complement factor H-derived short consensus repeat-antibody constructs | Medizinische Universität Innsbruck (AT) | 2010-07-21 | — | — | EP | disclosed |
| US-7744870-B1 | ST receptor binding compounds and methods of using the same | THOMAS JEFFERSON UNIVERSITY (US) | 2010-06-29 | — | — | US | disclosed |
| WO-2010070380-A2 | DOC1 COMPOSITIONS AND METHODS FOR TREATING CANCER | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH OF HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH (US) | 2010-06-24 | — | — | WO | disclosed |
| EP-1272665-B1 | COMPOSITIONS AND METHODS FOR IDENTIFYING AND TARGETING CANCER CELLS OF ALIMENTARY CANAL ORIGIN | UNIV JEFFERSON (US) | 2010-05-26 | — | — | EP | disclosed |
| US-20100120679-A1 | Targeting NBS1-ATM Interaction To Sensitize Cancer Cells To Radiotherapy And Chemotherapy | SOUTHERN RESEARCH INSTITUTE (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100093623-A1 | COMPOSITIONS AND METHODS FOR MODULATING NOD-LIKE RECEPTOR ACTIVITY AND USES THEREOF | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-04-15 | — | — | US | disclosed |
| EP-2164329-A2 | TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION | The Burnham Institute for Medical Research (US) | 2010-03-24 | — | — | EP | disclosed |
| WO-2010021415-A1 | METHOD FOR CONTROLLING CANCER METASTASIS OR CANCER CELL MIGRATION BY MODULATING THE CELLULAR LEVEL OF LYSYL TRNA SYNTHETASE | SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) | 2010-02-25 | — | — | WO | disclosed |
| EP-2155894-A2 | TARGETING HOST PROTEINASES AS A THERAPEUTIC STRATEGY AGAINST VIRAL AND BACTERIAL PATHOGENS | Burnham Institute for Medical Research (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2010009350-A2 | COMPOSITIONS AND METHODS FOR MODULATING NOD-LIKE RECEPTOR ACTIVITY AND USES THEREOF | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-01-21 | — | — | WO | disclosed |
| US-20100015167-A1 | COMPOSITIONS AND METHODS FOR IDENTIFYING AND TARGETING CANCER CELLS OF ALIMENTARY CANAL ORIGIN | THOMAS JEFFERSON UNIVERSITY | 2010-01-21 | — | — | US | disclosed |
| EP-1274861-B1 | COMPOSITIONS AND METHODS FOR IDENTIFYING AND TARGETING CANCER CELLS | UNIV JEFFERSON (US) | 2009-12-23 | — | — | EP | disclosed |
| WO-2009148709-A1 | PHARMACOLOGICAL TARGETING OF VASCULAR MALFORMATIONS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2009-12-10 | — | — | WO | disclosed |
| WO-2009136671-A1 | P53 REGULATORY PROTEIN AND USES THEREOF | SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) | 2009-11-12 | — | — | WO | disclosed |
| EP-2111876-A2 | Crosslinked polymer compositions and methods for their use | AngioDevice International GmbH (CH) | 2009-10-28 | — | — | EP | disclosed |
| WO-2009102349-A9 | SENSORS FOR MEASURING CONTAMINANTS | ECI BIOTECH INC. (US) | 2009-10-08 | — | — | WO | disclosed |
| US-20090233993-A1 | COMPOSITIONS AND METHODS FOR INHIBITING GSK3 ACTIVITY AND USES THEREOF | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-09-17 | — | — | US | disclosed |
| US-20090226372-A1 | METHODS AND COMPOSITIONS RELATED TO PEPTIDES AND PROTEINS WITH C-TERMINAL ELEMENTS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-09-10 | — | — | US | disclosed |
| WO-2009105671-A2 | METHODS AND COMPOSITIONS RELATED TO PEPTIDES AND PROTEINS WITH C-TERMINAL ELEMENTS CROSS-REFERENCE TO RELATED APPLICATIONS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-08-27 | — | — | WO | disclosed |
| EP-2091964-A2 | TARGETING NBS1-ATM INTERACTION TO SENSITIZE CANCER CELLS TO RADIOTHERAPY AND CHEMOTHERAPY | Southern Research Institute (US) | 2009-08-26 | — | — | EP | disclosed |
| WO-2009102349-A2 | SENSORS FOR MEASURING CONTAMINANTS | ECI BIOTECH INC. (US) | 2009-08-20 | — | — | WO | disclosed |
| WO-2009100218-A2 | KRUPPEL-LIKE TRANSCRIPTION FACTOR KLF4/GKLF AND USES THEREOF | UAB RESEARCH FOUNDATION (US) | 2009-08-13 | — | — | WO | disclosed |
| EP-1996607-A4 | LYMPHATIC ZIP CODES IN TUMORS AND PRE-MALIGNANT LESIONS | BURNHAM INST MEDICAL RESEARCH (US) | 2009-06-24 | — | — | EP | disclosed |
| US-20090156560-A1 | TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2009-06-18 | — | — | US | disclosed |
| WO-2009062520-A1 | DIAGNOSTIC USE OF INDIVIDUAL MOLECULAR FORMS OF A BIOMARKER | BIOPORTO DIAGNOSTICS A/S (DK) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009023306-A2 | TARGETING HOST PROTEINASES AS A THERAPEUTIC STRATEGY AGAINST VIRAL AND BACTERIAL PATHOGENS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-02-19 | — | — | WO | disclosed |
| WO-2009017863-A2 | TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009018429-A2 | TREATMENT OF CANCER VIA TARGETING OF IL-13 RECEPTOR-α2 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, ASREPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALT OF HUMAN SERVICES, NATIONAL INSTITUTES OF HEALT (US) | 2009-02-05 | — | — | WO | disclosed |
| US-20090029924-A1 | Targeting Host Proteinases as a Therapeutic Strategy Against Viral and Bacterial Pathogens | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-01-29 | — | — | US | disclosed |
| US-20090010935-A1 | Compositions and Methods of Treating Tumors | NIH - DEITR | 2009-01-08 | — | — | US | disclosed |
| EP-1996607-A2 | LYMPHATIC ZIP CODES IN TUMORS AND PRE-MALIGNANT LESIONS | The Burnham Institute for Medical Research (US) | 2008-12-03 | — | — | EP | disclosed |
| EP-1991587-A2 | HYDRAZIDO DERIVATIVES OF HYALURONIC ACID | ProChon Biotech Ltd. (IL) | 2008-11-19 | — | — | EP | disclosed |
| EP-1988910-A2 | ACRYLOYLOXYETHYLPHOSPHORYLCHOLINE CONTAINING POLYMER CONJUGATES AND THEIR PREPARATION | Oligasis Corporation (US) | 2008-11-12 | — | — | EP | disclosed |
| US-7439229-B2 | Cytokine activity regulator molecules from tick salivary glands | EVOLUTEC LIMITED (GB) | 2008-10-21 | — | — | US | disclosed |
| US-20080241064-A1 | COMPOSITIONS AND METHODS FOR IDENTIFYING AND TARGETING CANCER CELLS OF ALIMENTARY CANAL ORIGIN | THOMAS JEFFERSON UNIVERSITY | 2008-10-02 | — | — | US | disclosed |
| US-20080220438-A1 | Telomerase Promoter Sequences for Screening Telomerase Modulators | GERON CORPORATION | 2008-09-11 | — | — | US | disclosed |
| EP-1966234-A2 | ENDOMETRIOSIS CELL TARGETING PEPTIDES AND USES THEREOF | The Burnham Institute for Medical Research (US) | 2008-09-10 | — | — | EP | disclosed |
| EP-1956085-A2 | Carbohydrate crosslinked glycoprotein crystals | Altus Pharmaceuticals Inc. (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1009759-B1 | CARBOHYDRATE CROSSLINKED GLYCOPROTEIN CRYSTALS | ALTUS PHARMACEUTICALS INC (US) | 2008-05-28 | — | — | EP | disclosed |
| US-7378244-B2 | Telomerase promoters sequences for screening telomerase modulators | GERON CORPORATION (US) | 2008-05-27 | — | — | US | disclosed |
| WO-2008054726-A2 | TARGETING NBS1-ATM INTERACTION TO SENSITIZE CANCER CELLS TO RADIOTHERAPY AND CHEMOTHERAPY | SOUTHERN RESEARCH INSTITUTE (US) | 2008-05-08 | — | — | WO | disclosed |
| US-20080096836-A1 | Screening method | NUTTALL PATRICIA A | 2008-04-24 | — | — | US | disclosed |
| US-7344833-B2 | Methods and compositions for modulating activator protein 1 | IRM LLC (BM) | 2008-03-18 | — | — | US | disclosed |
| EP-1080201-B1 | NOVEL POST-TRANSCRIPTIONAL REGULATORY ELEMENTS AND USES THEREOF | US GOV HEALTH & HUMAN SERV (US) | 2008-01-23 | — | — | EP | disclosed |
| US-7316902-B2 | Compositions that specifically bind to colorectal cancer cells and methods of using the same | THOMAS JEFFERSON UNIVERSITY (US) | 2008-01-08 | — | — | US | disclosed |
| US-7279276-B2 | Screening method | EVOLUTEC LIMITED (GB) | 2007-10-09 | — | — | US | disclosed |
| WO-2007102149-A2 | HYDRAZIDO DERIVATIVES OF HYALURONIC ACID | PROCHON BIOTECH LTD. (IL) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007100905-A2 | ACRYLOYLOXYETHYLPHOSPHORYLCHOLINE CONTAINING POLYMER CONJUGATES AND THEIR PREPARATION | NEXGEN THERAPEUTICS, LLC (US) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007100902-A2 | ACRYLOYLOXYETHYLPHOSPHORYLCHOLINE CONTAINING POLYMER CONJUGATES AND THEIR PREPARATION | OLIGASIS CORPORATION (US) | 2007-09-07 | — | — | WO | disclosed |
| US-20070184522-A1 | Cell death modulation via antagonists of Fasl and Fas activation | UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2007-08-09 | — | — | US | disclosed |
| WO-2007090194-A2 | LYMPHATIC ZIP CODES IN TUMORS AND PRE-MALIGNANT LESIONS | THE BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2007-08-09 | — | — | WO | disclosed |
| US-7252944-B2 | Methods and compositions for modulating cell proliferation | IRM LLC (BM) | 2007-08-07 | — | — | US | disclosed |
| WO-2007076501-A2 | ENDOMETRIOSIS CELL TARGETING PEPTIDE AND USES THEREOF | THE BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2007-07-05 | — | — | WO | disclosed |
| EP-1572976-A4 | MODULATING IMMUNE RESPONSES | CELLTECH R & D INC (US) | 2007-05-09 | — | — | EP | disclosed |
| EP-1781339-A1 | COMPOUNDS OF THE INVENTIONS OF GUANYLYL CYCLASE C | THOMAS JEFFERSON UNIVERSITY (US) | 2007-05-09 | — | — | EP | disclosed |
| EP-1737483-A2 | CELL DEATH MODULATION VIA ANTAGONISTS OF FASL AND FAS ACTIVATION | University of Pittsburgh of the Commonwealth System of Higher Education (US) | 2007-01-03 | — | — | EP | disclosed |
| US-20060281106-A1 | Telomerase promoter sequences for screening telomerase modulators | GERON CORPORATION | 2006-12-14 | — | — | US | disclosed |
| US-20060269477-A1 | ST receptor binding compounds and methods of using the same | THOMAS JEFFERSON UNIVERSITY | 2006-11-30 | — | — | US | disclosed |
| US-7135333-B1 | Compositions that specifically bind to colorectal cancer cells and methods of using the same | THOMAS JEFFERSON UNIVERSITY (US) | 2006-11-14 | — | — | US | disclosed |
| EP-1704878-A2 | Crosslinked polymer compositions and methods for their use | AngioDevice International GmbH (CH) | 2006-09-27 | — | — | EP | disclosed |
| US-7097839-B1 | ST receptor binding compounds and methods of using the same | THOMAS JEFFERSON UNIVERSITY (US) | 2006-08-29 | — | — | US | disclosed |
| US-20060188872-A1 | Novel post-transcriptional regulatory elements and uses thereof | THE GOV. OF THE USA AS REPRESENTED BY THE SECRETARY DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2006-08-24 | — | — | US | disclosed |
| US-7087728-B2 | Carbohydrate crosslinked glycoprotein crystals | ALTUS PHARMACEUTICALS INC. (US) | 2006-08-08 | — | — | US | disclosed |
| WO-2005117940-A9 | CELL DEATH MODULATION VIA ANTAGONISTS OF FASL AND FAS ACTIVATION | UNIV PITTSBURGH (US) | 2006-08-03 | — | — | WO | disclosed |
| WO-2006012264-A1 | COMPOUNDS OF THE INVENTIONS OF GUANYLYL CYCLASE C | THOMAS JEFFERSON UNIVERSITY (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20050287067-A1 | Compounds of the inventions of guanylyl cyclase C | THOMAS JEFFERSON UNIVERSITY | 2005-12-29 | — | — | US | disclosed |
| WO-2005117940-A2 | CELL DEATH MODULATION VIA ANTAGONISTS OF FASL AND FAS ACTIVATION | UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2005-12-15 | — | — | WO | disclosed |
| EP-1274861-A4 | COMPOSITIONS AND METHODS FOR IDENTIFYING AND TARGETING CANCER CELLS | UNIV JEFFERSON (US) | 2005-09-28 | — | — | EP | disclosed |
| EP-1572976-A2 | MODULATING IMMUNE RESPONSES | Celltech R & D, Inc. (US) | 2005-09-14 | — | — | EP | disclosed |
| US-6919442-B1 | Nucleic acids comprising a post-transcriptional regulatory element (PRE) and their uses | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-07-19 | — | — | US | disclosed |
| US-20050123904-A1 | Methods and compositions for modulating herpesviral replication and transcription activator | IRM LLC (BM) | 2005-06-09 | — | — | US | disclosed |
| US-20050118663-A1 | Methods and compositions for modulating cell proliferation | IRM LLC (BM) | 2005-06-02 | — | — | US | disclosed |
| US-20050100895-A1 | Compositions and methods for identifying and targeting stomach and esophageal cancer cells | THOMAS JEFFERSON UNIVERSITY | 2005-05-12 | — | — | US | disclosed |
| EP-1247102-B1 | SCREENING FOR HOST-MOLECULES INTERACTING WITH PARASITE-SGE-RELATED COMPOUNDS | EVOLUTEC LTD (GB) | 2005-04-06 | — | — | EP | disclosed |
| US-6867022-B1 | Replication deficient adenovirus vectors and methods of making and using them | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2005-03-15 | — | — | US | disclosed |
| US-20050048585-A1 | Methods and compositions for modulating NF-AT transcription factor | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2005-03-03 | — | — | US | disclosed |
| WO-2005019478-A1 | METHODS AND COMPOSITIONS FOR MODULATING HERPESVIRAL REPLICATION AND TRANSCRIPTION ACTIVATOR | IRM LLC (BM) | 2005-03-03 | — | — | WO | disclosed |
| US-6858409-B1 | Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors | AMGEN INC. (US) | 2005-02-22 | — | — | US | disclosed |
| US-20050037390-A1 | Methods and compositions for modulating erythropoietin expression | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2005-02-17 | — | — | US | disclosed |
| EP-1206252-A4 | AMPLIFICATION OF FOLATE-MEDIATED TARGETING TO TUMOR CELLS USING POLYMERS | ACCESS PHARMACEUTICALS AUSTRAL (AU) | 2005-02-16 | — | — | EP | disclosed |
| WO-2005012577-A1 | METHODS AND COMPOSITIONS FOR MODULATING CELL PROLIFERATION | IRM LLC (BM) | 2005-02-10 | — | — | WO | disclosed |
| EP-1272665-A4 | COMPOSITIONS AND METHODS FOR IDENTIFYING AND TARGETING CANCER CELLS OF ALIMENTARY CANAL ORIGIN | UNIV JEFFERSON (US) | 2005-01-12 | — | — | EP | disclosed |
| WO-2005001136-A1 | METHODS AND COMPOSITIONS FOR MODULATING ERYTHROPOIETIN EXPRESSION | IRM LLC (BM) | 2005-01-06 | — | — | WO | disclosed |
| US-20050003387-A1 | Methods and compositions for modulating apoptosis | IRM LLC (BM) | 2005-01-06 | — | — | US | disclosed |
| US-20040259827-A1 | Compositions and methods for the abrogation of cellular proliferation utilizing the human immunodeficiency virus Vpr protein | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE | 2004-12-23 | — | — | US | disclosed |
| US-6815575-B1 | FOR IDENTIFYING GENES THAT PREVENT CELL/TISSUE (NEURAL, MUSCLE, MESODERM, KIDNEY) DEGRADATION/APOPTOSIS USING TRANSGENIC DROSOPHILA | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2004-11-09 | — | — | US | disclosed |
| US-20040185040-A1 | Modulating immune responses | CELLTECH R & D LIMITED (GB) | 2004-09-23 | — | — | US | disclosed |
| WO-2004075839-A2 | METHODS AND COMPOSITIONS FOR MODULATING APOPTOSIS | IRM LLC (BM) | 2004-09-10 | — | — | WO | disclosed |
| US-20040171035-A1 | Methods and compositions for modulating P53 transcription factor | IRM LLC (BM) | 2004-09-02 | — | — | US | disclosed |
| US-6777203-B1 | NUCLEIC ACIDS COMPRISING TELOMERASE REVERSE TRANSCRIPTASE (TERT) CIS-ACTING TRANSCRIPTIONAL CONTROL SEQUENCES, INCLUDING TERT HUMAN AND MOUSE PROMOTER SEQUENCES | GERON CORPORATION | 2004-08-17 | — | — | US | disclosed |
| US-20040146954-A1 | Compositions that specifically bind to colorectal cancer cells and methods of using the same | THOMAS JEFFERSON UNIVERSITY (US) | 2004-07-29 | — | — | US | disclosed |
| US-20040146903-A1 | Methods and compositions for modulating activator protein 1 | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2004-07-29 | — | — | US | disclosed |
| US-6767704-B2 | EXAMINING INTESTINAL TISSUE AND/OR BODY FLUIDS FOR EXPRESSION OF PROTEIN FOR NORMAL COLON CELLS INDICATING POSSIBILITY OF METASTATIC STOMACH OR ESOPHAGEAL CANCER CELLS | THOMAS JEFFERSON UNIVERSITY | 2004-07-27 | — | — | US | disclosed |
| WO-2004054506-A2 | METHODS AND COMPOSITIONS FOR MODULATING NF-AT TRANSCRIPTION FACTOR | IRM LLC (BM) | 2004-07-01 | — | — | WO | disclosed |
| WO-2004048552-A2 | MODULATING IMMUNE RESPONSES | CELLTECH R & D, INC. (US) | 2004-06-10 | — | — | WO | disclosed |
| WO-2004043370-A2 | METHODS AND COMPOSITIONS FOR MODULATING ACTIVATOR PROTEIN 1 | IRM LLC (BM) | 2004-05-27 | — | — | WO | disclosed |
| WO-2004043371-A2 | METHODS AND COMPOSITIONS FOR MODULATING P53 TRANSCRIPTION FACTOR | IRM LLC (BM) | 2004-05-27 | — | — | WO | disclosed |
| EP-1147181-B1 | REPLICATIVE VIRUS DRIVEN BY THE PROMOTER FOR TELOMERASE REVERSE TRANSCRIPTASE FOR USE IN TREATING CANCER | GERON CORP (US) | 2004-05-12 | — | — | EP | disclosed |
| US-20040072787-A1 | Telomerase reverse transcriptase transcriptional regulatory sequences and methods of using | GERON CORPORATION | 2004-04-15 | — | — | US | disclosed |
| EP-1392255-A1 | NANOPARTICLES MADE OF PROTEIN WITH COUPLED APOLIPOPROTEIN E FOR PENETRATION OF THE BLOOD-BRAIN BARRIER AND METHODS FOR THE PRODUCTION THEREOF | LTS Lohmann Therapie-Systeme AG (DE) | 2004-03-03 | — | — | EP | disclosed |
| US-20040033520-A1 | Compositions and methods for identifying and targeting cancer cells of alimentary canal origin | WALDMAN SCOTT A (US) | 2004-02-19 | — | — | US | disclosed |
| EP-0734264-B1 | COMPOSITIONS THAT SPECIFICALLY BIND TO COLORECTAL CANCER CELLS AND METHODS OF USING THE SAME | UNIV JEFFERSON (US) | 2004-02-18 | — | — | EP | disclosed |
| US-20040029182-A1 | ST receptor binding compounds and methods of using the same | WALDMAN SCOTT A (US) | 2004-02-12 | — | — | US | disclosed |
| US-6667157-B1 | Compositions and methods for the abrogation of cellular proliferation utilizing the human immunodeficiency virus VPR protein | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2003-12-23 | — | — | US | disclosed |
| US-20030204859-A1 | Animal model of polyglutamine toxicity, methods of use, and modulators of polyglutamine toxicity | CALIFORNIA INSTITUTE OF TECHNOLOGY, A CALIFORNIA CORPORATION | 2003-10-30 | — | — | US | disclosed |
| US-20030170843-A1 | Carbohydrate crosslinked glycoprotein crystals | ALTUS BIOLOGICS INC. | 2003-09-11 | — | — | US | disclosed |
| US-20030143638-A1 | Antibody/carrier complex, process for producing the same, method of controlling antigen-antibody reaction by using the same and immunoassay method | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 2003-07-31 | — | — | US | disclosed |
| WO-2001073133-A9 | COMPOSITIONS AND METHODS FOR IDENTIFYING AND TARGETING CANCER CELLS | UNIV JEFFERSON (US) | 2003-06-12 | — | — | WO | disclosed |
| EP-0575545-B1 | PEGYLATION OF POLYPEPTIDES | AMGEN INC (US) | 2003-05-21 | — | — | EP | disclosed |
| US-20030054417-A1 | Epithelial protein lost in neoplasm (EPLIN) | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2003-03-20 | — | — | US | disclosed |
| US-20030050244-A1 | Cytokine activity regulator molecules from tick salivary glands | EVOLUTEC LIMITED (GB) | 2003-03-13 | — | — | US | disclosed |
| US-20030044412-A1 | Membrane estrogen receptor-directed therapy in breast cancer | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2003-03-06 | — | — | US | disclosed |
| EP-1274861-A1 | COMPOSITIONS AND METHODS FOR IDENTIFYING AND TARGETING CANCER CELLS | Thomas Jefferson University (US) | 2003-01-15 | — | — | EP | disclosed |
| US-20030008333-A1 | Screening method | EVOLUTEC LIMITED (GB) | 2003-01-09 | — | — | US | disclosed |
| WO-2001053504-A9 | REPLICATION DEFICIENT ADENOVIRUS VECTORS | UNIV MICHIGAN MEDICAL SCHOOL (US) | 2003-01-09 | — | — | WO | disclosed |
| EP-1272665-A1 | COMPOSITIONS AND METHODS FOR IDENTIFYING AND TARGETING CANCER CELLS OF ALIMENTARY CANAL ORIGIN | Thomas Jefferson University (US) | 2003-01-08 | — | — | EP | disclosed |
| US-6500933-B1 | STABILIZATION OF GLYCOPROTEINS SUCH AS LIPASE OR OXIDASE VIA CRYSTALLIZATION AND CARBOHYDRATE-TO-CARBOHYDRATE CROSSLINKING WITHIN THE CRYSTAL LATTICE, USING TWO DIFFERENT CROSSLINKING AGENTS; VARIOUS MEDICAL, COSMETIC AND INDUSTRIAL USES | ALTUS BIOLOGICS INC. | 2002-12-31 | — | — | US | disclosed |
| US-20020187128-A1 | Novel replication deficient adenovirus vectors and methods for making and using them | UNIVERSITY OF MICHIGAN (US) | 2002-12-12 | — | — | US | disclosed |
| EP-1261371-A1 | MEMBRANE ESTROGEN RECEPTOR-DIRECTED THERAPY IN BREAST CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2002-12-04 | — | — | EP | disclosed |
| WO-2002089776-A1 | NANOPARTICLES MADE OF PROTEIN WITH COUPLED APOLIPOPROTEIN E FOR PENETRATION OF THE BLOOD-BRAIN BARRIER AND METHODS FOR THE PRODUCTION THEREOF | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2002-11-14 | — | — | WO | disclosed |
| US-20020165193-A1 | Anticancer agents; administering nucleic acid which dimerizes with protein | NIH - DEITR | 2002-11-07 | — | — | US | disclosed |
| EP-1254168-A2 | CYTOKINE INHIBITTORY MOLECULES FROM TICK SALIVARY GLANDS | Evolutec Limited (GB) | 2002-11-06 | — | — | EP | disclosed |
| EP-1252321-A1 | REPLICATION DEFICIENT ADENOVIRUS VECTORS | University of Michigan Medical School (US) | 2002-10-30 | — | — | EP | disclosed |
| EP-1247102-A2 | SCREENING FOR HOST-MOLECULES INTERACTING WITH PARASITE-SGE-RELATED COMPOUNDS | Evolutec Limited (GB) | 2002-10-09 | — | — | EP | disclosed |
| US-20020137899-A1 | Crosslinked through one or more carbohydrate moieties in said glycoprotein; storage stability, chemical stability over wider range of conditions while retaining bioactivity in use | ALTUS BIOLOGICS INC. | 2002-09-26 | — | — | US | disclosed |
| EP-1003769-A4 | COMPOSITIONS THAT SPECIFICALLY BIND TO COLORECTAL CANCER CELLS AND METHODS OF USING THE SAME | UNIV JEFFERSON (US) | 2002-08-21 | — | — | EP | disclosed |
| WO-2002055728-A2 | COMPOSITIONS AND METHODS FOR REGULATING RECEPTOR CLUSTERING | MOUNT SINAI HOSPITAL CORP (CA) | 2002-07-18 | — | — | WO | disclosed |
| EP-1206252-A1 | AMPLIFICATION OF FOLATE-MEDIATED TARGETING TO TUMOR CELLS USING POLYMERS | BIOTECH AUSTRALIA PTY. LIMITED (AU) | 2002-05-22 | — | — | EP | disclosed |
| US-20020042075-A1 | Sample presentation apparatus for mass spectrometry | NELSON RANDALL W (US) | 2002-04-11 | — | — | US | disclosed |
| WO-2002022885-A1 | COMPOSITIONS AND METHODS FOR IDENTIFYING AND TARGETING STOMACH AND ESOPHAGEAL CANCER CELLS | THOMAS JEFFERSON UNIVERSITY (US) | 2002-03-21 | — | — | WO | disclosed |
| US-6359118-B2 | STABLITY; USEFUL IN DRUGS, VACCINES, PERSONAL CARE/COSMETICS, VETERINARY DRUGS/VACCINES, FOODS, FEEDS, DIAGNOSTICS, CLEANING AGENTS (DETERGENTS AND DECONTAMINANTS); CATALYTIC AND BINDING COMPONENTS OF BIOSENSORS | ALTUS BIOLOGIES, INC. | 2002-03-19 | — | — | US | disclosed |
| US-6316266-B1 | PROVIDING MASS SPECTROMETRY SAMPLE PRESENTATION METAL SURFACE; CONTACTING COMPLEX WITH SURFACE TO FORM A SURFACE-BOUND COMPLEX; CONTACTING BIOMOLECULE WITH COMPLEX; APPLYING MATRIX ASSISTED LASER DESORPTION/IONIZATION MATRIX; DETERMINATION | ARIZONA STATE UNIVERSITY BOARD OF REGENTS | 2001-11-13 | — | — | US | disclosed |
| US-20010036635-A1 | Compositions and methods for identifying and targeting cancer cells of alimentary canal origin | THOMAS JEFFERSON UNIVERSITY | 2001-11-01 | — | — | US | disclosed |
| EP-1147181-A2 | TELOMERASE REVERSE TRANSCRIPTASE TRANSCRIPTIONAL REGULATORY SEQUENCES | Geron Corporation (US) | 2001-10-24 | — | — | EP | disclosed |
| US-20010029019-A1 | Compositions and methods for identifying and targeting cancer cells of alimentary canal origin | THOMAS JEFFERSON UNIVERSITY | 2001-10-11 | — | — | US | disclosed |
| WO-2001073133-A1 | COMPOSITIONS AND METHODS FOR IDENTIFYING AND TARGETING CANCER CELLS | THOMAS JEFFERSON UNIVERSITY (US) | 2001-10-04 | — | — | WO | disclosed |
| WO-2001073132-A1 | COMPOSITIONS AND METHODS FOR IDENTIFYING AND TARGETING CANCER CELLS OF ALIMENTARY CANAL ORIGIN | THOMAS JEFFERSON UNIVERSITY (US) | 2001-10-04 | — | — | WO | disclosed |
| US-20010018189-A1 | Methods and compositions for modulating heterotypic E-cadherin interactions with T lymphocytes | BRIGHAM AND WOMEN'S HOSPITAL, INC., THE | 2001-08-30 | — | — | US | disclosed |
| WO-2001062288-A1 | MEMBRANE ESTROGEN RECEPTOR-DIRECTED THERAPY IN BREAST CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-08-30 | — | — | WO | disclosed |
| WO-2001058941-A1 | CYTOKINE ACTIVITY REGULATOR MOLECULES FROM TICK SALIVARY GLANDS | EVOLUTEC LIMITED (GB) | 2001-08-16 | — | — | WO | disclosed |
| US-6268159-B1 | VISUALIZING TUMOR CELLS; ADMINISTER RADIOACTIVE PARTICLES TO HUMANS AND DETECT POSITIONING AND ACCUMULATION OF RADIOACTIVE PARTICLES IN BODY | THOMAS JEFFERSON UNIVERSITY | 2001-07-31 | — | — | US | disclosed |
| WO-2001053504-A1 | REPLICATION DEFICIENT ADENOVIRUS VECTORS | UNIVERSITY OF MICHIGAN MEDICAL SCHOOL (US) | 2001-07-26 | — | — | WO | disclosed |
| US-20010008934-A1 | CARBOHYDRATE CROSSLINKED GLYCOPROTEIN CRYSTALS | ALTHEA TECHNOLOGIES, INC. | 2001-07-19 | — | — | US | disclosed |
| WO-2001048484-A2 | SCREENING FOR HOST-MOLECULES INTERACTING WITH PARASITE-SGE-RELATED COMPOUNDS | EVOLUTEC LIMITED (GB) | 2001-07-05 | — | — | WO | disclosed |
| EP-1080201-A2 | NOVEL POST-TRANSCRIPTIONAL REGULATORY ELEMENTS AND USES THEREOF | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-03-07 | — | — | EP | disclosed |
| WO-2001012238-A1 | AN ANIMAL MODEL OF POLYGLUTAMINE TOXICITY, METHODS OF USE, AND MODULATORS OF POLYGLUTAMINE TOXICITY | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2001-02-22 | — | — | WO | disclosed |
| US-6187536-B1 | Methods of identifying and detecting pancreatic cancer | THOMAS JEFFERSON UNIVERSITY | 2001-02-13 | — | — | US | disclosed |
| EP-1073421-A1 | STABILIZED PROTEIN CRYSTALS, FORMULATIONS CONTAINING THEM AND METHODS OF MAKING THEM | Altus Biologics Inc. (US) | 2001-02-07 | — | — | EP | disclosed |
| WO-2000066091-A1 | AMPLIFICATION OF FOLATE-MEDIATED TARGETING TO TUMOR CELLS USING POLYMERS | BIOTECH AUSTRALIA PTY LIMITED (AU) | 2000-11-09 | — | — | WO | disclosed |
| US-6120995-A | IN VITRO METHOD OF DIAGNOSING METASTASIZED COLORECTAL CANCER BY DETECTING GENE EXPRESSION OF COLORECTAL CANCER-ASSOCIATED TRANSCRIPT-1, AN ALTERNATE FORM OF HEAT-STABLE TOXIN RECEPTOR, IN CELLS OF SAMPLE | THOMAS JEFFERSON UNIVERSITY (US) | 2000-09-19 | — | — | US | disclosed |
| WO-2000046355-A2 | TELOMERASE REVERSE TRANSCRIPTASE TRANSCRIPTIONAL REGULATORY SEQUENCES | GERON CORPORATION (US) | 2000-08-10 | — | — | WO | disclosed |
| EP-1009759-A1 | CARBOHYDRATE CROSSLINKED GLYCOPROTEIN CRYSTALS | Altus Biologics Inc. (US) | 2000-06-21 | — | — | EP | disclosed |
| EP-1003769-A1 | COMPOSITIONS THAT SPECIFICALLY BIND TO COLORECTAL CANCER CELLS AND METHODS OF USING THE SAME | THOMAS JEFFERSON UNIVERSITY (US) | 2000-05-31 | — | — | EP | disclosed |
| EP-0998309-A1 | METHODS AND SYSTEMS FOR PREPARING AND SEALING RADIATION DELIVERY STRUCTURES | INNERDYNE MEDICAL, INC. (US) | 2000-05-10 | — | — | EP | disclosed |
| US-6060037-A | CONJUGATED COMPOUNDS WHICH COMPRISE AN ST RECEPTOR BINDING MOIETY AND A RADIOSTABLE ACTIVE MOIETY | THOMAS JEFFERSON UNIVERSITY (US) | 2000-05-09 | — | — | US | disclosed |
| EP-0973878-A1 | CONTROLLED DISSOLUTION CROSS-LINKED PROTEIN CRYSTALS | Altus Biologics Inc. (US) | 2000-01-26 | — | — | EP | disclosed |
| WO-1999061596-A2 | NOVEL POST-TRANSCRIPTIONAL REGULATORY ELEMENTS AND USES THEREOF | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-12-02 | — | — | WO | disclosed |
| WO-1999055310-A1 | STABILIZED PROTEIN CRYSTALS, FORMULATIONS CONTAINING THEM AND METHODS OF MAKING THEM | ALTUS BIOLOGICS INC. (US) | 1999-11-04 | — | — | WO | disclosed |
| WO-1999033992-A1 | MURINE INTRACISTERNAL A PARTICLE CONSTITUTIVE TRANSPORT ELEMENTS AND USES THEREOF | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-07-08 | — | — | WO | disclosed |
| EP-0758196-A4 | COMPOSITIONS AND METHODS OF TREATING TUMORS | UNIV PENNSYLVANIA (US) | 1999-05-06 | — | — | EP | disclosed |
| EP-0734264-A4 | COMPOSITIONS THAT SPECIFICALLY BIND TO COLORECTAL CANCER CELLS AND METHODS OF USING THE SAME | UNIV JEFFERSON (US) | 1999-04-21 | — | — | EP | disclosed |
| WO-1999012959-A1 | CARBOHYDRATE CROSSLINKED GLYCOPROTEIN CRYSTALS | ALTUS BIOLOGICS INC. (US) | 1999-03-18 | — | — | WO | disclosed |
| US-5879656-A | RADIOACTIVE THERAPEUTIC AGENT, RECEPTOR BINDING MOIETY | THOMAS JEFFERSON UNIVERSITY (US) | 1999-03-09 | — | — | US | disclosed |
| US-5874417-A | A CROSSLINKED COMPOSITION HAVING CONJUGATED SITE AT GLUCURONIC ACID WITH A MONO HYDRAZIDE OR A POLYHYDRAZIDE AND A PLURALITY OF CELLS FOR TISSUE ENGINEERING, A COSMETIC AGENT, AND A DRUG; DRUG DELIVERY | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1999-02-23 | — | — | US | disclosed |
| WO-1999007726-A1 | COMPOSITIONS THAT SPECIFICALLY BIND TO COLORECTAL CANCER CELLS AND METHODS OF USING THE SAME | THOMAS JEFFERSON UNIVERSITY (US) | 1999-02-18 | — | — | WO | disclosed |
| WO-1999002194-A1 | METHODS AND SYSTEMS FOR PREPARING AND SEALING RADIATION DELIVERY STRUCTURES | INNERDYNE, INC. (US) | 1999-01-21 | — | — | WO | disclosed |
| EP-0832201-A4 | A SAMPLE PRESENTATION APPARATUS FOR MASS SPECTROMETRY | UNIV ARIZONA (US) | 1998-11-25 | — | — | EP | disclosed |
| WO-1998046732-A1 | CONTROLLED DISSOLUTION CROSS-LINKED PROTEIN CRYSTALS | ALTUS BIOLOGICS INC. (US) | 1998-10-22 | — | — | WO | disclosed |
| WO-1998035707-A1 | COMPOSITIONS THAT BIND TO PANCREATIC CANCER CELLS AND METHODS OF USING THE SAME | THOMAS JEFFERSON UNIVERSITY (US) | 1998-08-20 | — | — | WO | disclosed |
| US-5763190-A | DETECTING THE HUMAN IMMUNODEFICIENCY VIRUS TYPE I PROTEIN | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1998-06-09 | — | — | US | disclosed |
| EP-0832201-A1 | A SAMPLE PRESENTATION APPARATUS FOR MASS SPECTROMETRY | ARIZONA BOARD OF REGENTS (US) | 1998-04-01 | — | — | EP | disclosed |
| US-5637471-A | Therapeutic and diagnostic methods and compositions based on transducin-like enhancer of split proteins and nucleic acids | YALE UNIVERSITY (US) | 1997-06-10 | — | — | US | disclosed |
| US-5616568-A | Functionalized derivatives of hyaluronic acid | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1997-04-01 | — | — | US | disclosed |
| EP-0758196-A1 | COMPOSITIONS AND METHODS OF TREATING TUMORS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1997-02-19 | — | — | EP | disclosed |
| WO-1996040888-A1 | A SAMPLE PRESENTATION APPARATUS FOR MASS SPECTROMETRY | ARIZONA BOARD OF REGENTS (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0734264-A1 | COMPOSITIONS THAT SPECIFICALLY BIND TO COLORECTAL CANCER CELLS AND METHODS OF USING THE SAME | THOMAS JEFFERSON UNIVERSITY (US) | 1996-10-02 | — | — | EP | disclosed |
| US-5518888-A | IMAGING METASTASIZED COLORECTAL CANCER, TOXTIN PEPTIDES LESS THAN 25 UNITS | THOMAS JEFFERSON UNIVERSITY (US) | 1996-05-21 | — | — | US | disclosed |
| WO-1996008970-A1 | COMPOSITIONS AND METHODS FOR THE ABROGATION OF CELLULAR PROLIFERATION UTILIZING THE HUMAN IMMUNODEFICIENCY VIRUS Vpr PROTEIN | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1996-03-28 | — | — | WO | disclosed |
| WO-1995030331-A1 | COMPOSITIONS AND METHODS OF TREATING TUMORS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1995-11-16 | — | — | WO | disclosed |
| WO-1995015168-A1 | FUNCTIONALIZED DERIVATIVES OF HYALURONIC ACID | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1995-06-08 | — | — | WO | disclosed |
| WO-1995011694-A1 | COMPOSITIONS THAT SPECIFICALLY BIND TO COLORECTAL CANCER CELLS AND METHODS OF USING THE SAME | THOMAS JEFFERSON UNIVERSITY (US) | 1995-05-04 | — | — | WO | disclosed |
| EP-0575545-A4 | PEGYLATION OF POLYPEPTIDES. | SYNERGEN INC (US) | 1995-02-08 | — | — | EP | disclosed |
| US-5338428-A | Poly(N-Acylalkylenimine) electrophoresis support media | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1994-08-16 | — | — | US | disclosed |
| WO-1994008037-A9 | HUMAN HOMOLOGS OF THE TRANSDUCIN-LIKE ENHANCER OF SPLIT GENE AND METHODS BASED THEREON | — | 1994-05-26 | — | — | WO | disclosed |
| WO-1994007522-A9 | THERAPEUTIC AND DIAGNOSTIC METHODS AND COMPOSITIONS BASED ON TRANSDUCIN-LIKE ENHANCER OF SPLIT PROTEINS AND NUCLEIC ACIDS | — | 1994-05-26 | — | — | WO | disclosed |
| WO-1994007522-A1 | THERAPEUTIC AND DIAGNOSTIC METHODS AND COMPOSITIONS BASED ON TRANSDUCIN-LIKE ENHANCER OF SPLIT PROTEINS AND NUCLEIC ACIDS | YALE UNIVERSITY (US) | 1994-04-14 | — | — | WO | disclosed |
| WO-1994008037-A1 | HUMAN HOMOLOGS OF THE TRANSDUCIN-LIKE ENHANCER OF SPLIT GENE AND METHODS BASED THEREON | YALE UNIVERSITY (US) | 1994-04-14 | — | — | WO | disclosed |
| EP-0359996-B1 | Synthetic amino acid-and/or peptide-containing graft copolymers | AL MARZOOK UNITED COMMERCIAL C (KW) | 1994-04-13 | — | — | EP | disclosed |
| EP-0575545-A1 | PEGYLATION OF POLYPEPTIDES | SYNERGEN, INC. (US) | 1993-12-29 | — | — | EP | disclosed |
| WO-1992016221-A1 | PEGYLATION OF POLYPEPTIDES | SYNERGEN, INC. (US) | 1992-10-01 | — | — | WO | disclosed |
| US-5015677-A | Coatings, crosslinking, water-impervious, underwater adhesion, corrosion resistance, primers, orthopedics, dentistry, attaching tissue or grafts, sealing wounds, implanting prosthesis or medical device, ultrafiltration, plant treatment | BIO-POLYMERS, INC. (US) | 1991-05-14 | — | — | US | disclosed |
| EP-0359996-A2 | Synthetic amino acid-and/or peptide-containing graft copolymers | Al Marzook United Commercial Co. (KW) | 1990-03-28 | — | — | EP | disclosed |
| US-4908404-A | Water soluble high molecular weight cationic graft polymer | BIOPOLYMERS, INC. (US) | 1990-03-13 | — | — | US | disclosed |
| US-4908404-A | Water soluble high molecular weight cationic graft polymer | BIOPOLYMERS, INC. (US) | 1990-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (44 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150037359-A1 | XTEN CONJUGATE COMPOSITIONS AND METHODS OF MAKING SAME | XPA, TXLNA, NGLY1 | MME 220/4885KMT2A 2178/4885MEN1 455/4885 |
| US-12280021-B2 | Affinity medicant conjugate | FCER2, HDGF, FCGR2A | MME 16/4885KMT2A 573/4885MEN1 518/4885 |
| US-20100120679-A1 | Targeting NBS1-ATM Interaction To Sensitize Cancer Cells To Radiotherapy And Chemotherapy | ATM, MRE11, DCLRE1A | MME 4178/4885KMT2A 2930/4885MEN1 1738/4885 |
| US-20200268832-A1 | COMPOSITIONS FOR DELIVERY TO AND TREATMENT OF ATHEROSCLEROTIC PLAQUES | LDLR, MSR1, CX3CR1 | MME 563/4885KMT2A 3976/4885MEN1 4416/4885 |
| US-20140161725-A1 | Molecular Imaging of Cancer Cells In Vivo | MKI67, ANXA4, ANXA3 | MME 2091/4885KMT2A 4517/4885MEN1 430/4885 |
| US-11378572-B2 | Therapeutic agent for immune cell migration-caused disease and method for screening same | NFATC1, MIF, MMP8 | MME 3760/4885KMT2A 1486/4885MEN1 4060/4885 |
| US-10590201-B2 | Nucleic acids encoding antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease | DNASE1L3, RNASE1, TRDMT1 | MME 1945/4885KMT2A 1915/4885MEN1 2520/4885 |
| US-20210299063-A1 | AFFINITY MEDICANT CONJUGATE | FCER2, HDGF, FCGR2A | MME 16/4885KMT2A 573/4885MEN1 518/4885 |
| US-20090226372-A1 | METHODS AND COMPOSITIONS RELATED TO PEPTIDES AND PROTEINS WITH C-TERMINAL ELEMENTS | CD2BP2, CLTC, CLTA | MME 316/4885KMT2A 4721/4885MEN1 1667/4885 |
| US-10172953-B2 | XTEN conjugate compositions and methods of making same | XPA, TXLNA, NGLY1 | MME 220/4885KMT2A 2178/4885MEN1 455/4885 |
| US-20100322862-A1 | METHODS AND COMPOSITIONS USING PEPTIDES AND PROTEINS WITH C-TERMINAL ELEMENTS | CD2BP2, CLTC, CLTB | MME 392/4885KMT2A 4737/4885MEN1 1687/4885 |
| US-20210322518-A1 | XTEN CONJUGATE COMPOSITIONS AND METHODS OF MAKING SAME | XPA, TXLNA, NGLY1 | MME 220/4885KMT2A 2178/4885MEN1 455/4885 |
| US-20220096643-A1 | Acryloyloxyethylphosphorylcholine Containing Polymer Conjugates And Their Preparation | PHOSPHO1, PCTP, SGMS1 | MME 1692/4885KMT2A 1288/4885MEN1 899/4885 |
| US-10370245-B2 | Methods and compositions using peptides and proteins with C-terminal elements | CD2BP2, CLTC, CLTB | MME 392/4885KMT2A 4737/4885MEN1 1687/4885 |
| US-12599624-B2 | Biodegradable lung sealants | CD44, TTPA, PLOD3 | MME 3114/4885KMT2A 2895/4885MEN1 2333/4885 |
| US-20160145308-A1 | Compositions and Methods for Targeted Endometriosis Treatment | ESR2, ESRRG, ESRRB | MME 2163/4885KMT2A 2678/4885MEN1 4655/4885 |
| US-20030143638-A1 | Antibody/carrier complex, process for producing the same, method of controlling antigen-antibody reaction by using the same and immunoassay method | CD79B, CD99, PA2G4 | MME 1820/4885KMT2A 2801/4885MEN1 1158/4885 |
| US-10953073-B2 | XTEN conjugate compositions and methods of making same | XPA, TXLNA, NGLY1 | MME 220/4885KMT2A 2178/4885MEN1 455/4885 |
| US-11458212-B2 | Molecular imaging of cancer cells in vivo | MKI67, ANXA4, ANXA3 | MME 2091/4885KMT2A 4517/4885MEN1 430/4885 |
| US-20160053007-A1 | ANTIBODIES THAT BIND TO TL1A AND METHODS OF TREATING INFLAMMATORY OR AUTOIMMUNE DISEASE COMPRISING ADMINISTERING SUCH ANTIBODIES | TLL1, CD4, VCAM1 | MME 1565/4885KMT2A 3190/4885MEN1 1874/4885 |
| US-20230372267-A1 | AFFINITY MEDICANT CONJUGATE | FCER2, HDGF, FCGR2A | MME 16/4885KMT2A 573/4885MEN1 518/4885 |
| US-11260133-B2 | Methods and compositions related to peptides and proteins with C-terminal elements | CD2BP2, CLTC, CLTA | MME 316/4885KMT2A 4721/4885MEN1 1667/4885 |
| US-20120263718-A1 | BLOCKADE OF TL1A-DR3 INTERACTIONS TO AMELIORATE T CELL MEDIATED DISEASE PATHOLOGY AND ANTIBODIES THEREOF | TLL1, CD4, VCAM1 | MME 2365/4885KMT2A 3071/4885MEN1 2573/4885 |
| US-20120114682-A1 | PEPTIDES FOR BINDING FIBRINOGEN AND FIBRIN | FGB, F13B, KLKB1 | MME 681/4885KMT2A 3422/4885MEN1 2356/4885 |
| US-20180125988-A1 | TARGETED XTEN CONJUGATE COMPOSITIONS AND METHODS OF MAKING SAME | ADAM33, ADAM12, PTMS | MME 167/4885KMT2A 3455/4885MEN1 1560/4885 |
| US-20150079007-A1 | TUNABLE MULTIMODAL NANOPARTICLES AND METHODS OF USE THEREOF | CD47, AIP, PSMA3 | MME 3066/4885KMT2A 3607/4885MEN1 1716/4885 |
| US-20200141923-A1 | THERAPEUTIC AGENT FOR IMMUNE CELL MIGRATION-CAUSED DISEASE AND METHOD FOR SCREENING SAME | NFATC1, MIF, MMP8 | MME 3760/4885KMT2A 1486/4885MEN1 4060/4885 |
| US-20090233993-A1 | COMPOSITIONS AND METHODS FOR INHIBITING GSK3 ACTIVITY AND USES THEREOF | GSK3B, GSK3A, GSKIP | MME 723/4885KMT2A 3188/4885MEN1 2679/4885 |
| US-20170189550-A1 | SILICON PARTICLES TARGETING TUMOR CELLS | CD47, MSR1, SIK1 | MME 2177/4885KMT2A 3737/4885MEN1 440/4885 |
| US-20050287067-A1 | Compounds of the inventions of guanylyl cyclase C | GUCY1B2, GUCY1A1, GUCY1A2 | MME 1904/4885KMT2A 3971/4885MEN1 1381/4885 |
| US-10406248-B2 | Molecular imaging of cancer cells in vivo | MKI67, ANXA4, ANXA3 | MME 2091/4885KMT2A 4517/4885MEN1 430/4885 |
| US-20190083577-A1 | XTEN CONJUGATE COMPOSITIONS AND METHODS OF MAKING SAME | XPA, TXLNA, NGLY1 | MME 220/4885KMT2A 2178/4885MEN1 455/4885 |
| US-20180303898-A1 | COMPOSITIONS FOR DELIVERY TO AND TREATMENT OF ATHEROSCLEROTIC PLAQUES | LDLR, MSR1, CX3CR1 | MME 563/4885KMT2A 3976/4885MEN1 4416/4885 |
| US-20090156560-A1 | TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION | ALPL, CNDP2, ALPI | MME 539/4885KMT2A 2396/4885MEN1 3933/4885 |
| US-20180186888-A1 | ANTIBODIES THAT BIND TO TL1A AND METHODS OF TREATING INFLAMMATORY OR AUTOIMMUNE DISEASE COMPRISING ADMINISTERING SUCH ANTIBODIES | TLL1, CD4, VCAM1 | MME 1565/4885KMT2A 3190/4885MEN1 1874/4885 |
| US-20140220106-A1 | LYMPHATIC ZIP CODES IN TUMORS AND PRE-MALIGNANT LESIONS | SLC39A3, SLC39A11, CCL2 | MME 2295/4885KMT2A 3199/4885MEN1 2268/4885 |
| US-20100093623-A1 | COMPOSITIONS AND METHODS FOR MODULATING NOD-LIKE RECEPTOR ACTIVITY AND USES THEREOF | NOD2, NOD1, NLRP3 | MME 2075/4885KMT2A 4754/4885MEN1 4314/4885 |
| US-20160206747-A1 | Templated Nanoconjugates | NCL, EPCAM, CLTB | MME 2132/4885KMT2A 1700/4885MEN1 2235/4885 |
| US-20200164093-A1 | Molecular Imaging of Cancer Cells In Vivo | MKI67, ANXA4, ANXA3 | MME 2091/4885KMT2A 4517/4885MEN1 430/4885 |
| US-20120115785-A1 | ENDOTHELIAL NITRIC OXIDE SYNTHASE ANTAGONISTS AND USES THEREOF FOR INHIBITING OXYGEN TOXICITY | NOS1, NOS3, NOS2 | MME 1288/4885KMT2A 4604/4885MEN1 4823/4885 |
| US-20200156935-A1 | METHODS AND COMPOSITIONS USING PEPTIDES AND PROTEINS WITH C-TERMINAL ELEMENTS | CD2BP2, CLTC, CLTB | MME 392/4885KMT2A 4737/4885MEN1 1687/4885 |
| US-11576876-B2 | Affinity Medicant Conjugate | FCER2, HDGF, FCGR2A | MME 16/4885KMT2A 573/4885MEN1 518/4885 |
| US-20240091315-A1 | XTEN CONJUGATE COMPOSITIONS AND METHODS OF MAKING SAME | XPA, TXLNA, NGLY1 | MME 220/4885KMT2A 2178/4885MEN1 455/4885 |
| US-20090029924-A1 | Targeting Host Proteinases as a Therapeutic Strategy Against Viral and Bacterial Pathogens | SERPINB1, TMPRSS15, HPN | MME 22/4885KMT2A 4681/4885MEN1 1791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.